{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T11:02:58Z","timestamp":1789124578388,"version":"build-2803163510"},"reference-count":258,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s40272-022-00548-5","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T16:02:50Z","timestamp":1673366570000},"page":"165-191","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Treatment Options in Pediatric Beh\u00e7et\u2019s Disease"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9292-7601","authenticated-orcid":false,"given":"Teresa","family":"Giani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Flavia","family":"Luppino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,10]]},"reference":[{"key":"548_CR1","first-page":"2","volume":"2","author":"G Hatemi","year":"2022","unstructured":"Hatemi G, Seyahi E, Fresko I, Talarico R, U\u00e7ar D, Hamuryudan V. Beh\u00e7et\u2019s syndrome: one year in review 2022. Clin Exp Rheumatol. 2022;2:2.","journal-title":"Clin Exp Rheumatol"},{"key":"548_CR2","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1007\/s11739-021-02725-9","volume":"16","author":"J Sota","year":"2021","unstructured":"Sota J, Rigante D, Lopalco G, Emmi G, Gentileschi S, Gaggiano C, et al. Clinical profile and evolution of patients with juvenile-onset Beh\u00e7et\u2019s syndrome over a 25-year period: insights from the AIDA network. Intern Emerg Med. 2021;16:2163\u201371.","journal-title":"Intern Emerg Med"},{"key":"548_CR3","doi-asserted-by":"publisher","first-page":"390","DOI":"10.5152\/balkanmedj.2016.15101","volume":"33","author":"Y Ba\u015f","year":"2016","unstructured":"Ba\u015f Y, Se\u00e7kin HY, Kalkan G, Takc\u0131 Z, \u00d6nder Y, \u00c7\u0131t\u0131l R, et al. Investigation of Beh\u00e7et\u2019s disease and recurrent aphthous stomatitis frequency: the highest prevalence in Turkey. Balk Med J. 2016;33:390\u20135.","journal-title":"Balk Med J."},{"key":"548_CR4","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/art.24423","volume":"61","author":"KT Calamia","year":"2009","unstructured":"Calamia KT, Wilson FC, Icen M, Crowson CS, Gabriel SE, Kremers HM. Epidemiology and clinical characteristics of Beh\u00e7et\u2019s disease in the US: a population-based study. Arthritis Rheum. 2009;61:600\u20134.","journal-title":"Arthritis Rheum"},{"key":"548_CR5","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3315\/jdcr.2015.1213","volume":"9","author":"M Ndiaye","year":"2015","unstructured":"Ndiaye M, Sow AS, Valiollah A, Diallo M, Diop A, Alaoui RA, et al. Beh\u00e7et\u2019s disease in black skin: a retrospective study of 50 cases in Dakar. J Dermatol Case Rep. 2015;9:98\u2013102.","journal-title":"J Dermatol Case Rep."},{"key":"548_CR6","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s10067-010-1430-6","volume":"29","author":"F Davatchi","year":"2010","unstructured":"Davatchi F, Shahram F, Chams-Davatchi C, Shams H, Nadji A, Akhlaghi M, et al. Behcet\u2019s disease: from east to west. Clin Rheumatol. 2010;29:823\u201333.","journal-title":"Clin Rheumatol"},{"key":"548_CR7","first-page":"28","volume":"31","author":"I Olivieri","year":"2013","unstructured":"Olivieri I, Leccese P, Padula A, Nigro A, Palazzi C, Gilio M, et al. High prevalence of Beh\u00e7et\u2019s disease in southern Italy. Clin Exp Rheumatol. 2013;31:28\u201331.","journal-title":"Clin Exp Rheumatol"},{"key":"548_CR8","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1002\/art.24149","volume":"58","author":"A Mahr","year":"2008","unstructured":"Mahr A, Belarbi L, Wechsler B, Jeanneret D, Dhote R, Fain O, et al. Population-based prevalence study of Beh\u00e7et\u2019s disease: differences by ethnic origin and low variation by age at immigration. Arthritis Rheum. 2008;58:3951\u20139.","journal-title":"Arthritis Rheum"},{"key":"548_CR9","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/rheumatology\/kes249","volume":"52","author":"A Mohammad","year":"2013","unstructured":"Mohammad A, Mandl T, Sturfelt G, Segelmark M. Incidence, prevalence and clinical characteristics of Behcet\u2019s disease in southern Sweden. Rheumatology. 2013;52:304\u201310.","journal-title":"Rheumatology"},{"key":"548_CR10","first-page":"133","volume":"31","author":"I K\u00f6tter","year":"2004","unstructured":"K\u00f6tter I, Vonthein R, M\u00fcller CA, G\u00fcnaydin I, Zierhut M, St\u00fcbiger N. Beh\u00e7et\u2019s disease in patients of German and Turkish origin living in Germany: a comparative analysis. J Rheumatol. 2004;31:133\u20139.","journal-title":"J Rheumatol"},{"key":"548_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108381","volume":"214","author":"CE Pain","year":"2020","unstructured":"Pain CE. Juvenile-onset Beh\u00e7et\u2019s syndrome and mimics. Clin Immunol. 2020;214: 108381.","journal-title":"Clin Immunol"},{"key":"548_CR12","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00281-015-0502-8","volume":"37","author":"A G\u00fcl","year":"2015","unstructured":"G\u00fcl A. Pathogenesis of Beh\u00e7et\u2019s disease: autoinflammatory features and beyond. Semin Immunopathol. 2015;37:413\u20138.","journal-title":"Semin Immunopathol"},{"key":"548_CR13","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1093\/rheumatology\/38.12.1171","volume":"38","author":"CG Barnes","year":"1999","unstructured":"Barnes CG, Yazici H. Beh\u00e7et\u2019s syndrome. Rheumatology. 1999;38:1171\u20134.","journal-title":"Rheumatology"},{"key":"548_CR14","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/rheumatology\/ker428","volume":"51","author":"C Maldini","year":"2012","unstructured":"Maldini C, LaValley MP, Cheminant M, de Menthon M, Mahr A. Relationships of HLA-B51 or B5 genotype with Beh\u00e7et\u2019s disease clinical characteristics: systematic review and meta-analyses of observational studies. Rheumatology. 2012;51:887\u2013900.","journal-title":"Rheumatology"},{"key":"548_CR15","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1093\/rheumatology\/keab253","volume":"61","author":"A Filleron","year":"2021","unstructured":"Filleron A, Tran TA, Hubert A, Letierce A, Churlaud G, Kon\u00e9-Paut I, et al. Regulatory T cell\/Th17 balance in the pathogenesis of paediatric Beh\u00e7et disease. Rheumatology. 2021;61:422\u20139.","journal-title":"Rheumatology"},{"key":"548_CR16","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/ng.625","volume":"42","author":"EF Remmers","year":"2010","unstructured":"Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Beh\u00e7et\u2019s disease. Nat Genet. 2010;42:698\u2013702.","journal-title":"Nat Genet"},{"key":"548_CR17","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/ng.624","volume":"42","author":"N Mizuki","year":"2010","unstructured":"Mizuki N, Meguro A, Ota M, Ohno S, Shiota T, Kawagoe T, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Beh\u00e7et\u2019s disease susceptibility loci. Nat Genet. 2010;42:703\u20136.","journal-title":"Nat Genet"},{"key":"548_CR18","doi-asserted-by":"publisher","first-page":"27150","DOI":"10.3402\/jom.v7.27150","volume":"7","author":"N Seoudi","year":"2015","unstructured":"Seoudi N, Bergmeier LA, Drobniewski F, Paster B, Fortune F. The oral mucosal and salivary microbial community of Beh\u00e7et\u2019s syndrome and recurrent aphthous stomatitis. J Oral Microbiol. 2015;7:27150.","journal-title":"J Oral Microbiol"},{"key":"548_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0153746","volume":"11","author":"J Shimizu","year":"2016","unstructured":"Shimizu J, Kubota T, Takada E, Takai K, Fujiwara N, Arimitsu N, et al. Bifidobacteria abundance-featured gut microbiota compositional change in patients with Behcet\u2019s disease. PLoS ONE. 2016;11: e0153746.","journal-title":"PLoS ONE"},{"key":"548_CR20","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s10067-006-0349-4","volume":"26","author":"I Krause","year":"2007","unstructured":"Krause I, Yankevich A, Fraser A, Rosner I, Mader R, Zisman D, et al. Prevalence and clinical aspects of Behcet\u2019s disease in the north of Israel. Clin Rheumatol. 2007;26:555\u201360.","journal-title":"Clin Rheumatol"},{"key":"548_CR21","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12969-016-0070-z","volume":"14","author":"I Kon\u00e9-Paut","year":"2016","unstructured":"Kon\u00e9-Paut I. Beh\u00e7et\u2019s disease in children, an overview. Pediatr Rheumatol. 2016;14:10.","journal-title":"Pediatr Rheumatol"},{"key":"548_CR22","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.jaad.2007.10.452","volume":"58","author":"Y Karincaoglu","year":"2008","unstructured":"Karincaoglu Y, Borlu M, Toker SC, Akman A, Onder M, Gunasti S, et al. Demographic and clinical properties of juvenile-onset Beh\u00e7et\u2019s disease: a controlled multicenter study. J Am Acad Dermatol. 2008;58:579\u201384.","journal-title":"J Am Acad Dermatol"},{"key":"548_CR23","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s12016-012-8319-x","volume":"43","author":"H Yazici","year":"2012","unstructured":"Yazici H, Ugurlu S, Seyahi E. Beh\u00e7et syndrome: is it one condition? Clin Rev Allergy Immunol. 2012;43:275\u201380.","journal-title":"Clin Rev Allergy Immunol"},{"key":"548_CR24","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nrrheum.2017.208","volume":"14","author":"H Yazici","year":"2018","unstructured":"Yazici H, Seyahi E, Hatemi G, Yazici Y. Beh\u00e7et syndrome: a contemporary view. Nat Rev Rheumatol. 2018;14:107\u201319.","journal-title":"Nat Rev Rheumatol"},{"key":"548_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/rheumatology\/kez626","volume":"59","author":"A Bettiol","year":"2020","unstructured":"Bettiol A, Prisco D, Emmi G. Beh\u00e7et: the syndrome. Rheumatology (Oxford). 2020;59:101\u20137.","journal-title":"Rheumatology (Oxford)"},{"key":"548_CR26","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s11739-019-02046-y","volume":"14","author":"E Seyahi","year":"2019","unstructured":"Seyahi E. Phenotypes in Beh\u00e7et\u2019s syndrome. Intern Emerg Med. 2019;14:677\u201389.","journal-title":"Intern Emerg Med"},{"key":"548_CR27","first-page":"188","volume":"17","author":"J McHugh","year":"2021","unstructured":"McHugh J. Different phenotypes identified for Beh\u00e7et syndrome. Nat Rev Rheumatol. 2021;17:188.","journal-title":"Nat Rev Rheumatol"},{"key":"548_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13075-021-02429-7","volume":"23","author":"J Zou","year":"2021","unstructured":"Zou J, Luo JF, Shen Y, Cai JF, Guan JL. Cluster analysis of phenotypes of patients with Beh\u00e7et\u2019s syndrome: a large cohort study from a referral center in China. Arthritis Res Ther. 2021;23:45.","journal-title":"Arthritis Res Ther"},{"key":"548_CR29","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13075-020-02406-6","volume":"23","author":"Y Soejima","year":"2021","unstructured":"Soejima Y, Kirino Y, Takeno M, Kurosawa M, Takeuchi M, Yoshimi R, et al. Changes in the proportion of clinical clusters contribute to the phenotypic evolution of Beh\u00e7et\u2019s disease in Japan. Arthritis Res Ther. 2021;23:49.","journal-title":"Arthritis Res Ther"},{"key":"548_CR30","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1136\/annrheumdis-2015-208491","volume":"75","author":"I Kon\u00e9-Paut","year":"2016","unstructured":"Kon\u00e9-Paut I, Shahram F, Darce-Bello M, Cantarini L, Cimaz R, Gattorno M, et al. Consensus classification criteria for paediatric Beh\u00e7et\u2019s disease from a prospective observational cohort: PEDBD. Ann Rheum Dis. 2016;75:958\u201364.","journal-title":"Ann Rheum Dis"},{"key":"548_CR31","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3109\/09273948.2011.555592","volume":"19","author":"L Atmaca","year":"2011","unstructured":"Atmaca L, Boyvat A, Yal\u00e7\u0131nda\u011f FN, Atmaca-Sonmez P, Gurler A. Beh\u00e7et disease in children. Ocul Immunol Inflamm. 2011;19:103\u20137.","journal-title":"Ocul Immunol Inflamm"},{"key":"548_CR32","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/rheumatology\/keq324","volume":"50","author":"I Kon\u00e9-Paut","year":"2011","unstructured":"Kon\u00e9-Paut I, Darce-Bello M, Shahram F, Gattorno M, Cimaz R, Ozen S, et al. Registries in rheumatological and musculoskeletal conditions. Paediatric Beh\u00e7et\u2019s disease: an international cohort study of 110 patients One-year follow-up data. Rheumatology. 2011;50:184\u20138.","journal-title":"Rheumatology"},{"key":"548_CR33","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1007\/s10067-016-3187-z","volume":"35","author":"S Nanthapisal","year":"2016","unstructured":"Nanthapisal S, Klein NJ, Ambrose N, Eleftheriou D, Brogan PA. Paediatric Beh\u00e7et\u2019s disease: a UK tertiary centre experience. Clin Rheumatol. 2016;35:2509\u201316.","journal-title":"Clin Rheumatol"},{"key":"548_CR34","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12969-017-0213-x","volume":"15","author":"R Gallizzi","year":"2017","unstructured":"Gallizzi R, Pidone C, Cantarini L, Finetti M, Cattalini M, Filocamo G, et al. A national cohort study on pediatric Beh\u00e7et\u2019s disease: cross-sectional data from an Italian registry. Pediatr Rheumatol Online J. 2017;15:84.","journal-title":"Pediatr Rheumatol Online J"},{"key":"548_CR35","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.semarthrit.2020.01.013","volume":"50","author":"Y ButbulAviel","year":"2020","unstructured":"ButbulAviel Y, Batu ED, S\u00f6zeri B, Aktay Ayaz N, Baba L, Amarilyo G, et al. Characteristics of pediatric Beh\u00e7et\u2019s disease in Turkey and Israel: a cross-sectional cohort comparison. Semin Arthritis Rheum. 2020;50:515\u201320.","journal-title":"Semin Arthritis Rheum"},{"key":"548_CR36","doi-asserted-by":"crossref","first-page":"219","DOI":"10.4103\/0974-9233.58425","volume":"16","author":"I Tugal-Tutkun","year":"2009","unstructured":"Tugal-Tutkun I. Beh\u00e7et\u2019s uveitis. Middle East Afr J Ophthalmol. 2009;16:219\u201324.","journal-title":"Middle East Afr J Ophthalmol"},{"key":"548_CR37","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.jaapos.2009.04.016","volume":"13","author":"M Citirik","year":"2009","unstructured":"Citirik M, Berker N, Songur MS, Soykan E, Zilelioglu O. Ocular findings in childhood-onset Beh\u00e7et disease. J AAPOS. 2009;13:391\u20135.","journal-title":"J AAPOS"},{"key":"548_CR38","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.1016\/j.jfo.2019.02.002","volume":"42","author":"I Ksiaa","year":"2019","unstructured":"Ksiaa I, Abroug N, Kechida M, Zina S, Jelliti B, Khochtali S, et al. Eye and Beh\u00e7et\u2019s disease. J Fr Ophtalmol. 2019;42:e133\u201346.","journal-title":"J Fr Ophtalmol"},{"key":"548_CR39","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jaut.2009.02.011","volume":"32","author":"D Mendes","year":"2009","unstructured":"Mendes D, Correia M, Barbedo M, Vaio T, Mota M, Gon\u00e7alves O, et al. Beh\u00e7et\u2019s disease: a contemporary review. J Autoimmun. 2009;32:178\u201388.","journal-title":"J Autoimmun"},{"key":"548_CR40","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1136\/bjo.2008.154476","volume":"93","author":"N Kitaichi","year":"2009","unstructured":"Kitaichi N, Miyazaki A, Stanford MR, Iwata D, Chams H, Ohno S. Low prevalence of juvenile-onset Behcet\u2019s disease with uveitis in East\/South Asian people. Br J Ophthalmol. 2009;93:1428\u201330.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"548_CR41","first-page":"1","volume":"7","author":"M Y\u0131ld\u0131z","year":"2019","unstructured":"Y\u0131ld\u0131z M, K\u00f6ker O, Adrovic A, \u015eahin S, Barut K, Kasap\u00e7opur \u00d6. Pediatric Beh\u00e7et\u2019s disease: clinical aspects and current concepts. Eur J Rheumatol. 2019;7(1):1\u201310.","journal-title":"Eur J Rheumatol"},{"key":"548_CR42","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3899\/jrheum.100257","volume":"38","author":"B Krupa","year":"2011","unstructured":"Krupa B, Cimaz R, Ozen S, Fischbach M, Cochat P, Isabelle K-P. Pediatric Behcet\u2019s disease and thromboses. J Rheumatol. 2011;38:387\u201390.","journal-title":"J Rheumatol"},{"key":"548_CR43","first-page":"135","volume":"36","author":"F Shahram","year":"2018","unstructured":"Shahram F, Nadji A, Akhlaghi M, Faezi ST, Chams-Davatchi C, Shams H, et al. Paediatric Beh\u00e7et\u2019s disease in Iran: report of 204 cases. Clin Exp Rheumatol. 2018;36:135\u201340.","journal-title":"Clin Exp Rheumatol"},{"key":"548_CR44","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.clindermatol.2017.06.004","volume":"35","author":"I Bulur","year":"2017","unstructured":"Bulur I, Onder M. Beh\u00e7et disease: new aspects. Clin Dermatol. 2017;35:421\u201334.","journal-title":"Clin Dermatol"},{"key":"548_CR45","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/BOR.0b013e3283410088","volume":"23","author":"KT Calamia","year":"2011","unstructured":"Calamia KT, Schirmer M, Melikoglu M. Major vessel involvement in Beh\u00e7et\u2019s disease: an update. Curr Opin Rheumatol. 2011;23:24\u201331.","journal-title":"Curr Opin Rheumatol"},{"key":"548_CR46","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1136\/ard.43.6.783","volume":"43","author":"H Yazici","year":"1984","unstructured":"Yazici H, T\u00fcz\u00fcn Y, Pazarli H, Yurdakul S, Ozyazgan Y, Ozdo\u011fan H, et al. Influence of age of onset and patient\u2019s sex on the prevalence and severity of manifestations of Beh\u00e7et\u2019s syndrome. Ann Rheum Dis. 1984;43:783\u20139.","journal-title":"Ann Rheum Dis"},{"key":"548_CR47","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1750-1172-8-18","volume":"8","author":"P Mora","year":"2013","unstructured":"Mora P, Menozzi C, Orsoni JG, Rubino P, Ruffini L, Carta A. Neuro-Beh\u00e7et\u2019s disease in childhood: a focus on the neuro-ophthalmological features. Orphanet J Rare Dis. 2013;8:18.","journal-title":"Orphanet J Rare Dis"},{"key":"548_CR48","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1212\/WNL.0b013e318238edeb","volume":"77","author":"D Uluduz","year":"2011","unstructured":"Uluduz D, K\u00fcrt\u00fcnc\u00fc M, Yap\u0131c\u0131 Z, Seyahi E, Kasap\u00e7opur \u00d6, \u00d6zdo\u011fan H, et al. Clinical characteristics of pediatric-onset neuro-Beh\u00e7et disease. Neurology. 2011;77:1900\u20135.","journal-title":"Neurology"},{"key":"548_CR49","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s12016-020-08809-2","volume":"61","author":"YC Hu","year":"2021","unstructured":"Hu YC, Chiang BL, Yang YH. Clinical manifestations and management of pediatric Beh\u00e7et\u2019s disease. Clin Rev Allergy Immunol. 2021;61:171\u201380.","journal-title":"Clin Rev Allergy Immunol"},{"key":"548_CR50","first-page":"103","volume":"8","author":"EL Grigg","year":"2012","unstructured":"Grigg EL, Kane S, Katz S. Mimicry and deception in inflammatory bowel disease and intestinal beh\u00e7et disease. Gastroenterol Hepatol. 2012;8:103\u201312.","journal-title":"Gastroenterol Hepatol"},{"key":"548_CR51","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1007\/BF02235590","volume":"43","author":"IJ Choi","year":"2000","unstructured":"Choi IJ, Kim JS, Cha SD, Jung HC, Park JG, Song IS, et al. Long-term clinical course and prognostic factors in intestinal Beh\u00e7et\u2019s disease. Dis Colon Rectum. 2000;43:692\u2013700.","journal-title":"Dis Colon Rectum"},{"key":"548_CR52","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1055\/s-2000-9012","volume":"32","author":"JS Kim","year":"2000","unstructured":"Kim JS, Lim SH, Choi IJ, Moon H, Jung HC, Song IS, et al. Prediction of the clinical course of Beh\u00e7et\u2019s colitis according to macroscopic classification by colonoscopy. Endoscopy. 2000;32:635\u201340.","journal-title":"Endoscopy"},{"key":"548_CR53","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/00054725-200108000-00010","volume":"7","author":"CR Lee","year":"2001","unstructured":"Lee CR, Kim WH, Cho YS, Kim MH, Kim JH, Park IS, et al. Colonoscopic findings in intestinal Beh\u00e7et\u2019s disease. Inflamm Bowel Dis. 2001;7:243\u20139.","journal-title":"Inflamm Bowel Dis"},{"key":"548_CR54","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13052-017-0350-3","volume":"43","author":"R Gallizzi","year":"2017","unstructured":"Gallizzi R, De Vivo D, Valenti S, Pidone C, Romeo C, Caruso R, et al. Intestinal and neurological involvement in Behcet disease: a clinical case. Ital J Pediatr. 2017;43:33.","journal-title":"Ital J Pediatr"},{"key":"548_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.627192","volume":"8","author":"M Yildiz","year":"2021","unstructured":"Yildiz M, Haslak F, Adrovic A, Sahin S, Koker O, Barut K, et al. Pediatric Beh\u00e7et\u2019s disease. Front Med. 2021;8: 627192.","journal-title":"Front Med"},{"key":"548_CR56","doi-asserted-by":"publisher","first-page":"14405","DOI":"10.1073\/pnas.2002051117","volume":"117","author":"K Manthiram","year":"2020","unstructured":"Manthiram K, Preite S, Dedeoglu F, Demir S, Ozen S, Edwards KM, et al. Common genetic susceptibility loci link PFAPA syndrome, Beh\u00e7et\u2019s disease, and recurrent aphthous stomatitis. Proc Natl Acad Sci. 2020;117:14405\u201311.","journal-title":"Proc Natl Acad Sci"},{"issue":"10","key":"548_CR57","volume":"9","author":"S Pak","year":"2017","unstructured":"Pak S, Logemann S, Dee C, Fershko A. Breaking the magic: mouth and genital ulcers with inflamed cartilage syndrome. Cureus. 2017;9(10): e1743.","journal-title":"Cureus."},{"key":"548_CR58","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-0028-1103481","volume":"41","author":"SK Lee","year":"2009","unstructured":"Lee SK, Kim BK, Kim TI, Kim WH. Differential diagnosis of intestinal Beh\u00e7et\u2019s disease and Crohn\u2019s disease by colonoscopic findings. Endoscopy. 2009;41:9\u201316.","journal-title":"Endoscopy"},{"key":"548_CR59","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","volume":"77","author":"G Hatemi","year":"2018","unstructured":"Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F, et al. 2018 update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome. Ann Rheum Dis. 2018;77:808\u201318.","journal-title":"Ann Rheum Dis"},{"key":"548_CR60","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1093\/rheumatology\/key445","volume":"58","author":"C Papadopoulou","year":"2019","unstructured":"Papadopoulou C, Omoyinmi E, Standing A, Pain CE, Booth C, D\u2019Arco F, et al. Monogenic mimics of Beh\u00e7et\u2019s disease in the young. Rheumatology. 2019;58:1227\u201338.","journal-title":"Rheumatology"},{"key":"548_CR61","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/ng.3459","volume":"48","author":"Q Zhou","year":"2016","unstructured":"Zhou Q, Wang H, Schwartz DM, Stoffels M, Park YH, Zhang Y, et al. Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. Nat Genet. 2016;48:67\u201373.","journal-title":"Nat Genet"},{"key":"548_CR62","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.3390\/jcm11051278","volume":"11","author":"O Kul Cinar","year":"2022","unstructured":"Kul Cinar O, Romano M, Guzel F, Brogan PA, Demirkaya E. Paediatric Beh\u00e7et\u2019s disease: a comprehensive review with an emphasis on monogenic mimics. J Clin Med. 2022;11:1278.","journal-title":"J Clin Med"},{"key":"548_CR63","first-page":"1078","volume":"335","author":"Criteria for diagnosis of Beh\u00e7et\u2019s disease","year":"1990","unstructured":"Criteria for diagnosis of Beh\u00e7et\u2019s disease. International study group for Beh\u00e7et\u2019s disease. Lancet. 1990;335:1078\u201380.","journal-title":"Lancet"},{"key":"548_CR64","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/jdv.12107","volume":"28","author":"F Davatchi","year":"2014","unstructured":"Davatchi F, Assaad-Khalil S, Calamia KT, Crook JE, Sadeghi-Abdollahi B, et al. The International Criteria for Beh\u00e7et\u2019s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28:338\u201347.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Suppl. 108","key":"548_CR65","first-page":"119","volume":"35","author":"ED Batu","year":"2017","unstructured":"Batu ED, S\u00f6nmez HE, S\u00f6zeri B, ButbulAviel Y, Bilginer Y, \u00d6zen S. The performance of different classification criteria in paediatric Beh\u00e7et\u2019s disease. Clin Exp Rheumatol. 2017;35(Suppl. 108):119\u201323.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"548_CR66","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00296-018-4208-9","volume":"39","author":"ED Batu","year":"2019","unstructured":"Batu ED. Diagnostic\/classification criteria in pediatric Beh\u00e7et\u2019s disease. Rheumatol Int. 2019;39(1):37\u201346.","journal-title":"Rheumatol Int"},{"key":"548_CR67","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1007\/s10067-019-04570-w","volume":"38","author":"TA Gheita","year":"2019","unstructured":"Gheita TA, El-Latif EA, El-Gazzar II, Samy N, Hammam N, Abdel Noor RA, et al. Beh\u00e7et\u2019s disease in Egypt: a multicenter nationwide study on 1526 adult patients and review of the literature. Clin Rheumatol. 2019;38:2565\u201375.","journal-title":"Clin Rheumatol"},{"key":"548_CR68","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000018197","volume":"199","author":"R Treudler","year":"1999","unstructured":"Treudler R, Orfanos CE, Zouboulis CC. Twenty-eight cases of juvenile-onset Adamantiades-Beh\u00e7et disease in Germany. Dermatology. 1999;199:15\u20139.","journal-title":"Dermatology"},{"key":"548_CR69","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/j.1365-4632.2006.02754.x","volume":"45","author":"M Borlu","year":"2006","unstructured":"Borlu M, Uk\u015fal U, Ferahba\u015f A, Evereklioglu C. Clinical features of Beh\u00e7et\u2019s disease in children. Int J Dermatol. 2006;45:713\u20136.","journal-title":"Int J Dermatol"},{"key":"548_CR70","first-page":"748","volume":"52","author":"A Hamzaoui","year":"2014","unstructured":"Hamzaoui A, Jaziri F, Ben Salem T, Ghorbel SIB, et al. Comparison of clinical features of Behcet disease according to age in a Tunisian cohort. Acta Med Iran. 2014;52:748\u201351.","journal-title":"Acta Med Iran"},{"key":"548_CR71","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1111\/j.1365-2133.2007.08116.x","volume":"157","author":"E Alpsoy","year":"2007","unstructured":"Alpsoy E, Donmez L, Onder M, Gunasti S, Usta A, Karincaoglu Y, et al. Clinical features and natural course of Beh\u00e7et\u2019s disease in 661 cases: a multicentre study. Br J Dermatol. 2007;157:901\u20136.","journal-title":"Br J Dermatol"},{"key":"548_CR72","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1002\/art.27568","volume":"62","author":"D Saadoun","year":"2010","unstructured":"Saadoun D, Wechsler B, Desseaux K, Le Thi HD, Amoura Z, Resche-Rigon M, et al. Mortality in Beh\u00e7et\u2019s disease. Arthritis Rheum. 2010;62:2806\u201312.","journal-title":"Arthritis Rheum"},{"key":"548_CR73","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0022-3476(98)70368-3","volume":"132","author":"I Kon\u00e9-Paut","year":"1998","unstructured":"Kon\u00e9-Paut I, Yurdakul S, Bahabri SA, Shafae N, Ozen S, Ozdogan H, et al. Clinical features of Beh\u00e7et\u2019s disease in children: an international collaborative study of 86 cases. J Pediatr. 1998;132:721\u20135.","journal-title":"J Pediatr"},{"key":"548_CR74","doi-asserted-by":"crossref","unstructured":"Nakamura K, Iwata Y, Asai J, Kawakami T, Tsunemi Y, Takeuchi M, Mizuki N, Kaneko F; Members of the Consensus Conference on Treatment of Skin and Mucosal Lesions (Committee of Guideline for the Diagnosis and Treatment of Mucocutaneous Lesions of Beh\u00e7et's disease) Guidelines for the treatment of skin and mucosal lesions in Beh\u00e7et's disease: a secondary publication. J Dermatol. 2020;47(3):223\u201335","DOI":"10.1111\/1346-8138.15207"},{"key":"548_CR75","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/s13023-020-01620-4","volume":"16","author":"I Kone-Paut","year":"2021","unstructured":"Kone-Paut I, Barete S, Bodaghi B, Deiva K, Desbois AC, et al. French recommendations for the management of Beh\u00e7et\u2019s disease. Orphanet J Rare Dis. 2021;16:352.","journal-title":"Orphanet J Rare Dis"},{"key":"548_CR76","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1080\/14760584.2021.1875825","volume":"19","author":"HN Tse","year":"2020","unstructured":"Tse HN, Borrow R, Arkwright PD. Immune response and safety of viral vaccines in children with autoimmune diseases on immune modulatory drug therapy. Expert Rev Vaccines. 2020;19:1115\u201327.","journal-title":"Expert Rev Vaccines"},{"key":"548_CR77","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1136\/ard.2011.150193","volume":"70","author":"MW Heijstek","year":"2011","unstructured":"Heijstek MW, de Ott Bruin LM, Bijl M, Borrow R, van der Klis F, Kon\u00e9-Paut I, et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis. 2011;70:1704\u201312.","journal-title":"Ann Rheum Dis"},{"key":"548_CR78","first-page":"2","volume":"2","author":"RBM Landew\u00e9","year":"2022","unstructured":"Landew\u00e9 RBM, Kroon FPB, Alunno A, Najm A, Bijlsma JW, Burmester GRR, et al. EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. Ann Rheum Dis. 2022;2:2.","journal-title":"Ann Rheum Dis"},{"key":"548_CR79","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.1093\/rheumatology\/keab751","volume":"61","author":"F Tagini","year":"2022","unstructured":"Tagini F, Carrel L, Fallet B, Gachoud D, Ribi C, Monti M. Beh\u00e7et\u2019s-like adverse event or inaugural Beh\u00e7et\u2019s disease after SARS-CoV-2 mRNA-1273 vaccination? Rheumatology. 2022;61:e112\u20133.","journal-title":"Rheumatology"},{"key":"548_CR80","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.919979","volume":"13","author":"Y Xie","year":"2022","unstructured":"Xie Y, Liu Y, Liu Y. The flare of rheumatic disease after SARS-CoV-2 vaccination: a review. Front Immunol. 2022;13: 919979.","journal-title":"Front Immunol"},{"key":"548_CR81","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s00296-022-05119-y","volume":"42","author":"A Ozdede","year":"2022","unstructured":"Ozdede A, Guner S, Ozcifci G, Yurttas B, TokerDincer Z, Atli Z, et al. Safety of SARS-CoV-2 vaccination in patients with Behcet\u2019s syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine. Rheumatol Int. 2022;42:973\u201387.","journal-title":"Rheumatol Int"},{"key":"548_CR82","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jaad.2016.02.1239","volume":"76","author":"A Caplan","year":"2017","unstructured":"Caplan A, Fett N, Rosenbach M, Werth VP, Micheletti RG. Prevention and management of glucocorticoid-induced side effects: a comprehensive review. J Am Acad Dermatol. 2017;76:11\u20136.","journal-title":"J Am Acad Dermatol"},{"key":"548_CR83","first-page":"3","volume":"2","author":"C Sims","year":"2022","unstructured":"Sims C, Clowse MEB. A comprehensive guide for managing the reproductive health of patients with vasculitis. Nat Rev Rheumatol. 2022;2:3.","journal-title":"Nat Rev Rheumatol"},{"key":"548_CR84","first-page":"772","volume":"40","author":"I Mulla","year":"2022","unstructured":"Mulla I, Yeung RSM, Noone DG, Bell-Peter A, Pagnoux C. Paediatric-to-adult transition experience in vasculitis: report of a model of care and outcomes. Clin Exp Rheumatol. 2022;40:772\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"548_CR85","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/1346-8138.13381","volume":"43","author":"E Alpsoy","year":"2016","unstructured":"Alpsoy E. Beh\u00e7et\u2019s disease: a comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions. J Dermatol. 2016;43:620\u201332.","journal-title":"J Dermatol"},{"key":"548_CR86","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1093\/rheumatology\/keq251","volume":"49","author":"E Bernab\u00e9","year":"2010","unstructured":"Bernab\u00e9 E, Marcenes W, Mather J, Phillips C, Fortune F. Impact of Beh\u00e7et\u2019s syndrome on health-related quality of life: influence of the type and number of symptoms. Rheumatology. 2010;49:2165\u201371.","journal-title":"Rheumatology"},{"key":"548_CR87","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.613419","volume":"8","author":"G Mumcu","year":"2021","unstructured":"Mumcu G, Fortune F. Oral health and its aetiological role in Beh\u00e7et\u2019s disease. Front Med. 2021;8: 613419.","journal-title":"Front Med"},{"key":"548_CR88","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1093\/rheumatology\/keh236","volume":"43","author":"G Mumcu","year":"2004","unstructured":"Mumcu G. Oral health is impaired in Behcet\u2019s disease and is associated with disease severity. Rheumatology. 2004;43:1028\u201333.","journal-title":"Rheumatology"},{"key":"548_CR89","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1600-0714.2009.00867.x","volume":"39","author":"ST Kozlak","year":"2010","unstructured":"Kozlak ST, Walsh SJ, Lalla RV. Reduced dietary intake of vitamin B12 and folate in patients with recurrent aphthous stomatitis. J Oral Pathol Med. 2010;39:420\u20133.","journal-title":"J Oral Pathol Med"},{"key":"548_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/986203","volume":"2014","author":"G Soylu\u00d6zler","year":"2014","unstructured":"Soylu\u00d6zler G, Okuyucu \u015e, Ako\u011flu E. The efficacy of sucralfate and chlorhexidine as an oral rinse in patients with recurrent aphthous stomatitis. Adv Med. 2014;2014:1\u20133.","journal-title":"Adv Med"},{"key":"548_CR91","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1111\/ijd.12144","volume":"52","author":"G Mumcu","year":"2013","unstructured":"Mumcu G, \u0130nan\u00e7 N, \u00d6zdemir FT, Tulunay A, Ek\u015fio\u011flu-Demiralp E, Ergun T, et al. Effects of azithromycin on intracellular cytokine responses and mucocutaneous manifestations in Beh\u00e7et\u2019s disease. Int J Dermatol. 2013;52:1561\u20136.","journal-title":"Int J Dermatol"},{"key":"548_CR92","first-page":"95","volume":"31","author":"JA Ship","year":"2000","unstructured":"Ship JA, Chavez EM, Doerr PA, Henson BS, Sarmadi M. Recurrent aphthous stomatitis. Quintessence Int. 2000;31:95\u2013112.","journal-title":"Quintessence Int"},{"key":"548_CR93","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12903-019-0850-1","volume":"19","author":"D Dalessandri","year":"2019","unstructured":"Dalessandri D, Zotti F, Laffranchi L, Migliorati M, Isola G, Bonetti S, et al. Treatment of recurrent aphthous stomatitis (RAS; aphthae; canker sores) with a barrier forming mouth rinse or topical gel formulation containing hyaluronic acid: a retrospective clinical study. BMC Oral Health. 2019;19:153.","journal-title":"BMC Oral Health"},{"key":"548_CR94","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3109\/09546639209088723","volume":"3","author":"Y Ko\u00e7","year":"1992","unstructured":"Ko\u00e7 Y, Akpek G, Akpolat T, G\u00fcll\u00fc I, Kansu E, Kiraz S, et al. Topical sucralfate therapy for oral ulcers in Beh\u00e7et\u2019s disease: a randomized double-blind study. J Dermatol Treat. 1992;3:197\u20139.","journal-title":"J Dermatol Treat"},{"issue":"5","key":"548_CR95","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/archderm.135.5.529","volume":"135","author":"E Alpsoy","year":"1999","unstructured":"Alpsoy E, Er H, Durusoy C, Yilmaz E. The use of sucralfate suspension in the treatment of oral and genital ulceration of Beh\u00e7et disease: a randomized, placebo-controlled, double-blind study. Arch Dermatol. 1999;135(5):529\u201332.","journal-title":"Arch Dermatol"},{"key":"548_CR96","doi-asserted-by":"publisher","first-page":"444","DOI":"10.4103\/jpbs.JPBS_133_20","volume":"12","author":"K Kavita","year":"2020","unstructured":"Kavita K, Singh R, Singh R, Gonuguntla S, Luke AM, Jois HS. Assessment of efficacy of 5% topical Amlexanox and 0.1% topical triamcinolone acetonide in management of recurrent aphthous stomatitis. J Pharm Bioallied Sci. 2020;12:444\u20137.","journal-title":"J Pharm Bioallied Sci."},{"key":"548_CR97","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S1079-2104(97)90031-7","volume":"84","author":"MA Saxen","year":"1997","unstructured":"Saxen MA, Ambrosius WT, Rehemtula KF, Russell AL, Eckert GJ. Sustained relief of oral aphthous ulcer pain from topical diclofenac in hyaluronan: a randomized, double-blind clinical trial. Oral Surg Oral Med. 1997;84:356\u201361.","journal-title":"Oral Surg Oral Med"},{"key":"548_CR98","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.amjmed.2011.09.011","volume":"125","author":"C Liu","year":"2012","unstructured":"Liu C, Zhou Z, Liu G, Wang Q, Chen J, Wang L, et al. Efficacy and safety of dexamethasone ointment on recurrent aphthous ulceration. Am J Med. 2012;125:292\u2013301.","journal-title":"Am J Med"},{"key":"548_CR99","first-page":"75","volume":"14","author":"MM Fani","year":"2012","unstructured":"Fani MM, Ebrahimi H, Pourshahidi S, Aflaki E, Shafiee SS. Comparing the effect of phenytoin syrup and triamcinolone acetonide ointment on aphthous ulcers in patients with Behcet\u2019s syndrome. Iran Red Crescent Med J. 2012;14:75\u20138.","journal-title":"Iran Red Crescent Med J"},{"key":"548_CR100","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1093\/rheumatology\/30.5.395-a","volume":"30","author":"V Hamuryudan","year":"1991","unstructured":"Hamuryudan V, Yurdakul S, Rosenkaimer F, Yazici H. Inefficacy of topical alpha interferon in the treatment of oral ulcers of Beh\u00e7et\u2019s syndrome: a randomized, double blind trial. Br J Rheumatol. 1991;30:395\u20136.","journal-title":"Br J Rheumatol"},{"key":"548_CR101","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1093\/rheumatology\/kep237","volume":"48","author":"H Kili\u00e7","year":"2009","unstructured":"Kili\u00e7 H, Zeytin HE, Korkmaz C, Mat C, G\u00fcl A, Co\u015fan F, et al. Low-dose natural human interferon-alpha lozenges in the treatment of Beh\u00e7et\u2019s syndrome. Rheumatology. 2009;48:1388\u201391.","journal-title":"Rheumatology"},{"key":"548_CR102","first-page":"2","volume":"71","author":"G Hatemi","year":"2019","unstructured":"Hatemi G, Yurttas B, Kutlubay Z, Cote T, Derkunt S, Yazici Y, et al. Pentoxifylline gel for oral ulcers in patients with Beh\u00e7et\u2019s syndrome [abstract]. Arthritis Rheumatol. 2019;71:2.","journal-title":"Arthritis Rheumatol"},{"key":"548_CR103","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jbspin.2006.03.006","volume":"73","author":"E Niel","year":"2006","unstructured":"Niel E, Scherrmann JM. Colchicine today. Joint Bone Spine. 2006;73:672\u20138.","journal-title":"Joint Bone Spine"},{"key":"548_CR104","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.semarthrit.2015.06.013","volume":"45","author":"YY Leung","year":"2015","unstructured":"Leung YY, Yao Hui LL, Kraus VB. Colchicine; update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015;45:341\u201350.","journal-title":"Semin Arthritis Rheum"},{"key":"548_CR105","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2174\/1381612824666180123110042","volume":"24","author":"C Angelidis","year":"2018","unstructured":"Angelidis C, Kotsialou Z, Kossyvakis C, Vrettou AR, Zacharoulis A, Kolokathis F, et al. Colchicine pharmacokinetics and mechanism of action. Curr Pharm Des. 2018;24:659\u201363.","journal-title":"Curr Pharm Des"},{"key":"548_CR106","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1002\/art.30389","volume":"63","author":"RA Terkeltaub","year":"2011","unstructured":"Terkeltaub RA, Furst DE, Digiacinto JL, Kook KA, Davis MW. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4\/P-glycoprotein inhibitors. Arthritis Rheum. 2011;63:2226\u201337.","journal-title":"Arthritis Rheum"},{"key":"548_CR107","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/jop.13020","volume":"49","author":"M Cabras","year":"2020","unstructured":"Cabras M, Carrozzo M, Gambino A, Broccoletti R, Sciascia S, Baldovino S, et al. Value of colchicine as treatment for recurrent oral ulcers: a systematic review. J Oral Pathol Med. 2020;49:731\u201340.","journal-title":"J Oral Pathol Med"},{"key":"548_CR108","first-page":"399","volume":"65","author":"E Aktulga","year":"1980","unstructured":"Aktulga E, Alta\u00e7 M, M\u00fcft\u00fcoglu A, Ozyazgan Y, Pazarli H, T\u00fcz\u00fcn Y, et al. A double blind study of colchicine in Beh\u00e7et\u2019s disease. Haematologica. 1980;65:399\u2013402.","journal-title":"Haematologica"},{"key":"548_CR109","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1002\/1529-0131(200111)44:11<2686::AID-ART448>3.0.CO;2-H","volume":"44","author":"S Yurdakul","year":"2001","unstructured":"Yurdakul S, Mat C, T\u00fcz\u00fcn Y, Ozyazgan Y, Hamuryudan V, Uysal O, et al. A double-blind trial of colchicine in Beh\u00e7et\u2019s syndrome. Arthritis Rheum. 2001;44:2686\u201392.","journal-title":"Arthritis Rheum"},{"key":"548_CR110","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3109\/s10165-009-0200-2","volume":"19","author":"F Davatchi","year":"2009","unstructured":"Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A, Shahram F, Nadji A, Shams H, et al. Colchicine versus placebo in Beh\u00e7et\u2019s disease: randomized, double-blind, controlled crossover trial. Mod Rheumatol. 2009;19:542\u20139.","journal-title":"Mod Rheumatol"},{"key":"548_CR111","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/S0140-6736(89)92381-7","volume":"1","author":"K Masuda","year":"1989","unstructured":"Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Beh\u00e7et\u2019s disease. Lancet. 1989;1:1093\u20136.","journal-title":"Lancet"},{"key":"548_CR112","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/annrheumdis-2015-208690","volume":"75","author":"S Ozen","year":"2016","unstructured":"Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016;75:644\u201351.","journal-title":"Ann Rheum Dis"},{"key":"548_CR113","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1056\/NEJM199002013220501","volume":"322","author":"H Yazici","year":"1990","unstructured":"Yazici H, Pazarli H, Barnes CG, T\u00fcz\u00fcn Y, Ozyazgan Y, Silman A, et al. A controlled trial of azathioprine in Beh\u00e7et\u2019s syndrome. N Engl J Med. 1990;322:281\u20135.","journal-title":"N Engl J Med"},{"key":"548_CR114","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/ced.15019","volume":"47","author":"K Hussain","year":"2022","unstructured":"Hussain K, Patel P, Roberts N. The role of thalidomide in dermatology. Clin Exp Dermatol. 2022;47:667\u201374.","journal-title":"Clin Exp Dermatol"},{"key":"548_CR115","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1093\/rheumatology\/40.8.933","volume":"40","author":"JA Kari","year":"2001","unstructured":"Kari JA, Shah V, Dillon MJ. Beh\u00e7et\u2019s disease in UK children: clinical features and treatment including thalidomide. Rheumatology. 2001;40:933\u20138.","journal-title":"Rheumatology"},{"key":"548_CR116","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/ibd.20317","volume":"14","author":"K Yasui","year":"2008","unstructured":"Yasui K, Uchida N, Akazawa Y, Nakamura S, Minami I, Amano Y, et al. Thalidomide for treatment of intestinal involvement of juvenile-onset Beh\u00e7et disease. Inflamm Bowel Dis. 2008;14:396\u2013400.","journal-title":"Inflamm Bowel Dis"},{"key":"548_CR117","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1525-1470.1993.tb00377.x","volume":"10","author":"S Menni","year":"1993","unstructured":"Menni S, Imondi D, Brancaleone W, Croci S. Recurrent giant aphthous ulcers in a child: protracted treatment with thalidomide. Pediatr Dermatol. 1993;10:283\u20135.","journal-title":"Pediatr Dermatol"},{"key":"548_CR118","doi-asserted-by":"publisher","first-page":"443","DOI":"10.7326\/0003-4819-128-6-199803150-00004","volume":"128","author":"V Hamuryudan","year":"1998","unstructured":"Hamuryudan V. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;128:443.","journal-title":"Ann Intern Med"},{"key":"548_CR119","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1590\/S1807-59322009000300008","volume":"64","author":"MAM Mimura","year":"2009","unstructured":"Mimura MAM, Hirota SK, Sugaya NN, Sanches JA, Migliari DA. Systemic treatment in severe cases of recurrent aphthous stomatitis: an open trial. Clinics. 2009;64:193\u20138.","journal-title":"Clinics"},{"key":"548_CR120","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1346-8138.2002.tb00263.x","volume":"29","author":"KE Sharquie","year":"2002","unstructured":"Sharquie KE, Najim RA, Abu-Raghif AR. Dapsone in Beh\u00e7et\u2019s disease: a double-blind, placebo-controlled, cross-over study. J Dermatol. 2002;29:267\u201379.","journal-title":"J Dermatol"},{"key":"548_CR121","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/ijd.14761","volume":"59","author":"N Ghaoui","year":"2020","unstructured":"Ghaoui N, Hanna E, Abbas O, Kibbi AG, Kurban M. Update on the use of dapsone in dermatology. Int J Dermatol. 2020;59:787\u201395.","journal-title":"Int J Dermatol"},{"key":"548_CR122","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1056\/NEJMoa1408684","volume":"372","author":"G Hatemi","year":"2015","unstructured":"Hatemi G, Melikoglu M, Tunc R, Korkmaz C, Turgut Ozturk B, Mat C, et al. Apremilast for Beh\u00e7et\u2019s syndrome: a phase 2, placebo-controlled study. N Engl J Med. 2015;372:1510\u20138.","journal-title":"N Engl J Med"},{"issue":"Suppl. 132","key":"548_CR123","doi-asserted-by":"publisher","first-page":"80","DOI":"10.55563\/clinexprheumatol\/ra8ize","volume":"39","author":"G Hatemi","year":"2021","unstructured":"Hatemi G, Mahr A, Takeno M, Kim DY, Saadoun D, Direskeneli H, et al. Apremilast for oral ulcers associated with active Beh\u00e7et\u2019s syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial. Clin Exp Rheumatol. 2021;39(Suppl. 132):80\u20137.","journal-title":"Clin Exp Rheumatol"},{"key":"548_CR124","first-page":"98","volume":"2","author":"Y Iizuka","year":"2021","unstructured":"Iizuka Y, Takase-Minegishi K, Hirahara L, Kirino Y, Soejima Y, Namkoong H, et al. Beneficial effects of apremilast on genital ulcers, skin lesions, and arthritis in patients with Beh\u00e7et\u2019s disease: a systematic review and meta-analysis. Mod Rheumatol. 2021;2:98.","journal-title":"Mod Rheumatol"},{"key":"548_CR125","doi-asserted-by":"crossref","unstructured":"Arida A, Fragiadaki K, Giavri E, Sfikakis PP. Anti-TNF agents for Beh\u00e7et\u2019s disease: analysis of published data on 369 patients. Semin Arthritis Rheum. 2011;41:61\u201370.","DOI":"10.1016\/j.semarthrit.2010.09.002"},{"key":"548_CR126","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s12013-014-9860-4","volume":"69","author":"D Ma","year":"2014","unstructured":"Ma D, Zhang CJ, Wang RP, Wang L, Yang H. Etanercept in the treatment of intestinal Behcet\u2019s disease. Cell Biochem Biophys. 2014;69:735\u20139.","journal-title":"Cell Biochem Biophys"},{"key":"548_CR127","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1093\/rheumatology\/kes130","volume":"51","author":"D Perra","year":"2012","unstructured":"Perra D, Alba MA, Callejas JL, Mesquida M, R\u00edos-Fern\u00e1ndez R, Ad\u00e1n A, et al. Adalimumab for the treatment of Beh\u00e7et\u2019s disease: experience in 19 patients. Rheumatology. 2012;51:1825\u201331.","journal-title":"Rheumatology"},{"key":"548_CR128","first-page":"S94","volume":"28","author":"F Atzeni","year":"2010","unstructured":"Atzeni F, Leccese P, D\u2019Angelo S, Sarzi-Puttini P, Olivieri I. Successful treatment of leg ulcers in Beh\u00e7et\u2019s disease using adalimumab plus methotrexate after the failure of infliximab. Clin Exp Rheumatol. 2010;28:S94.","journal-title":"Clin Exp Rheumatol"},{"key":"548_CR129","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13075-017-1222-3","volume":"19","author":"PC Grayson","year":"2017","unstructured":"Grayson PC, Yazici Y, Merideth M, Sen HN, Davis M, Novakovich E, et al. Treatment of mucocutaneous manifestations in Beh\u00e7et\u2019s disease with anakinra: a pilot open-label study. Arthritis Res Ther. 2017;19:69.","journal-title":"Arthritis Res Ther"},{"key":"548_CR130","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000358125","volume":"228","author":"A Vitale","year":"2014","unstructured":"Vitale A, Rigante D, Caso F, Brizi MG, Galeazzi M, Costa L, et al. Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Beh\u00e7et\u2019s disease: a case series. Dermatology. 2014;228:211\u20134.","journal-title":"Dermatology"},{"key":"548_CR131","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jaut.2017.05.002","volume":"82","author":"A Mirouse","year":"2017","unstructured":"Mirouse A, Barete S, Monfort JB, Resche-Rigon M, Bouyer AS, Comarmond C, et al. Ustekinumab for Beh\u00e7et\u2019s disease. J Autoimmun. 2017;82:41\u20136.","journal-title":"J Autoimmun"},{"key":"548_CR132","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1136\/annrheumdis-2020-217108","volume":"79","author":"F Fagni","year":"2020","unstructured":"Fagni F, Bettiol A, Talarico R, Lopalco G, Silvestri E, Urban ML, et al. Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Beh\u00e7et\u2019s phenotype: a multicentre study. Ann Rheum Dis. 2020;79:1098\u2013104.","journal-title":"Ann Rheum Dis"},{"key":"548_CR133","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/omcr\/omz041","volume":"2019","author":"E Dincses","year":"2019","unstructured":"Dincses E, Yurttas B, Esatoglu SN, Melike M, Hamuryudan V, Seyahi E. Secukinumab induced Beh\u00e7et\u2019s syndrome: a report of two cases. Oxf Med Case Rep. 2019;2019:41.","journal-title":"Oxf Med Case Rep"},{"key":"548_CR134","doi-asserted-by":"publisher","first-page":"e587","DOI":"10.1111\/jdv.16454","volume":"34","author":"N Barrado-Sol\u00eds","year":"2020","unstructured":"Barrado-Sol\u00eds N, Rodrigo-Nicol\u00e1s B, De la Morena-Barrio I, P\u00e9rez-Pastor G, Sanchis-S\u00e1nchez C, Tom\u00e1s-Cabedo G, et al. Report of two cases of Beh\u00e7et\u2019s disease developed during treatment with secukinumab. J Eur Acad Dermatol Venereol. 2020;34:e587\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"548_CR135","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1093\/rheumatology\/ket130","volume":"52","author":"AP Diamantopoulos","year":"2013","unstructured":"Diamantopoulos AP, Hatemi G. Lack of efficacy of tocilizumab in mucocutaneous Behcet\u2019s syndrome: report of two cases. Rheumatology. 2013;52:1923\u20134.","journal-title":"Rheumatology"},{"key":"548_CR136","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s10067-014-2589-z","volume":"34","author":"L Cantarini","year":"2015","unstructured":"Cantarini L, Lopalco G, Vitale A, Coladonato L, Rigante D, Lucherini OM, et al. Paradoxical mucocutaneous flare in a case of Beh\u00e7et\u2019s disease treated with tocilizumab. Clin Rheumatol. 2015;34:1141\u20133.","journal-title":"Clin Rheumatol"},{"key":"548_CR137","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.semarthrit.2016.03.006","volume":"46","author":"G Emmi","year":"2016","unstructured":"Emmi G, Silvestri E, Squatrito D, Emmi L, Cantarini L, Prisco D. Tocilizumab-induced exacerbation of mucosal ulcers in a patient with multi-refractory Beh\u00e7et\u05f3s disease. Semin Arthritis Rheum. 2016;46:e1-2.","journal-title":"Semin Arthritis Rheum"},{"key":"548_CR138","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.clineuro.2011.10.024","volume":"114","author":"LS Shapiro","year":"2012","unstructured":"Shapiro LS, Farrell J, Borhani HA. Tocilizumab treatment for neuro-Behcet\u2019s disease, the first report. Clin Neurol Neurosurg. 2012;114:297\u20138.","journal-title":"Clin Neurol Neurosurg"},{"key":"548_CR139","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.semarthrit.2020.05.017","volume":"50","author":"M Akiyama","year":"2020","unstructured":"Akiyama M, Kaneko Y, Takeuchi T. Effectiveness of tocilizumab in Behcet\u2019s disease: a systematic literature review. Semin Arthritis Rheum. 2020;50:797\u2013804.","journal-title":"Semin Arthritis Rheum"},{"key":"548_CR140","doi-asserted-by":"publisher","first-page":"5174","DOI":"10.3390\/jcm10215174","volume":"10","author":"H Zaj\u0105c","year":"2021","unstructured":"Zaj\u0105c H, Turno-Kr\u0119cicka A. Ocular manifestations of Beh\u00e7et\u2019s disease: an update on diagnostic challenges and disease management. J Clin Med. 2021;10:5174.","journal-title":"J Clin Med"},{"key":"548_CR141","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1167\/iovs.13-12660","volume":"55","author":"JD Sheppard","year":"2014","unstructured":"Sheppard JD, Toyos MM, Kempen JH, Kaur P, Foster CS. Difluprednate 0.05% versus prednisolone acetate 1% for endogenous anterior uveitis: a phase III, multicenter, randomized study. Investig Opthalmology Vis Sci. 2014;55:2993.","journal-title":"Investig Opthalmology Vis Sci."},{"key":"548_CR142","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3109\/09273948.2013.866257","volume":"22","author":"M Zierhut","year":"2014","unstructured":"Zierhut M, Abu El-Asrar AM, Bodaghi B, Tugal-Tutkun I. Therapy of ocular Beh\u00e7et disease. Ocul Immunol Inflamm. 2014;22:64\u201376.","journal-title":"Ocul Immunol Inflamm"},{"key":"548_CR143","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1097\/ICU.0000000000000210","volume":"26","author":"C Fabiani","year":"2015","unstructured":"Fabiani C, Ali\u00f3 JL. Local (topical and intraocular) therapy for ocular Adamantiades-Beh\u00e7et\u02bcs disease. Curr Opin Ophthalmol. 2015;26:546\u201352.","journal-title":"Curr Opin Ophthalmol"},{"key":"548_CR144","doi-asserted-by":"publisher","first-page":"e299","DOI":"10.1111\/j.1755-3768.2010.02025.x","volume":"88","author":"Z Habot-Wilner","year":"2010","unstructured":"Habot-Wilner Z, Sallam A, Roufas A, Kabasele PM, Grigg JR, McCluskey P, et al. Periocular corticosteroid injection in the management of uveitis in children. Acta Ophthalmol. 2010;88:e299-304.","journal-title":"Acta Ophthalmol"},{"key":"548_CR145","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.4155\/tde.14.75","volume":"5","author":"PWJ Morrison","year":"2014","unstructured":"Morrison PWJ, Khutoryanskiy VV. Advances in ophthalmic drug delivery. Ther Deliv. 2014;5:1297\u2013315.","journal-title":"Ther Deliv"},{"key":"548_CR146","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/092739490500192","volume":"12","author":"PA Gaudio","year":"2004","unstructured":"Gaudio PA. A review of evidence guiding the use of corticosteroids in the treatment of intraocular inflammation. Ocul Immunol Inflamm. 2004;12:169\u201392.","journal-title":"Ocul Immunol Inflamm"},{"key":"548_CR147","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.2147\/OPTH.S89341","volume":"10","author":"HY Tan","year":"2016","unstructured":"Tan HY, Agarwal A, Lee CS, Chhablani J, Gupta V, Khatri M, et al. Management of noninfectious posterior uveitis with intravitreal drug therapy. Clin Ophthalmol. 2016;10:1983\u20132020.","journal-title":"Clin Ophthalmol"},{"key":"548_CR148","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.ajo.2014.09.003","volume":"158","author":"J Zarranz-Ventura","year":"2014","unstructured":"Zarranz-Ventura J, Carre\u00f1o E, Johnston RL, Mohammed Q, Ross AH, Barker C, et al. Multicenter study of intravitreal dexamethasone implant in noninfectious uveitis: indications, outcomes, and reinjection frequency. Am J Ophthalmol. 2014;158:1136-45.e5.","journal-title":"Am J Ophthalmol"},{"key":"548_CR149","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40123-014-0027-6","volume":"4","author":"VS Sangwan","year":"2015","unstructured":"Sangwan VS, Pearson PA, Paul H, Comstock TL. Use of the fluocinolone acetonide intravitreal implant for the treatment of noninfectious posterior uveitis: 3-year results of a randomized clinical trial in a predominantly Asian population. Ophthalmol Ther. 2015;4:1\u201319.","journal-title":"Ophthalmol Ther"},{"key":"548_CR150","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/09273940802553295","volume":"17","author":"A Mirshahi","year":"2009","unstructured":"Mirshahi A, Namavari A, Djalilian A, Moharamzad Y, Chams H. Intravitreal bevacizumab (Avastin) for the treatment of cystoid macular edema in Beh\u00e7et disease. Ocul Immunol Inflamm. 2009;17:59\u201364.","journal-title":"Ocul Immunol Inflamm"},{"key":"548_CR151","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.4103\/ijo.IJO_217_20","volume":"68","author":"D Ucar","year":"2020","unstructured":"Ucar D, Mergen B, Gonen B, Ozguler Y, Seyahi E, Hamuryudan V, et al. Investigation of clinical profile of Beh\u00e7et\u2019s syndrome-related versus idiopathic branch retinal vein occlusion. Indian J Ophthalmol. 2020;68:1876\u201380.","journal-title":"Indian J Ophthalmol"},{"key":"548_CR152","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1097\/IAE.0000000000003095","volume":"41","author":"M Refaat","year":"2021","unstructured":"Refaat M, Abdullatif AM, Hamza MM, Macky TA, El-Agha MSH, Ragab G, et al. Monthly intravitreal infliximab in Behcet\u2019s disease active posterior uveitis: a long-term safety study. Retina. 2021;41:1739\u201347.","journal-title":"Retina"},{"key":"548_CR153","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1002\/art.1780400425","volume":"40","author":"V Hamuryudan","year":"1997","unstructured":"Hamuryudan V, Ozyazgan Y, Hizli N, Mat C, Yurdakul S, T\u00fcz\u00fcn Y, et al. Azathioprine in Behcet\u2019s syndrome: effects on long-term prognosis. Arthritis Rheum. 1997;40:769\u201374.","journal-title":"Arthritis Rheum"},{"key":"548_CR154","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1002\/acr.20308","volume":"62","author":"D Saadoun","year":"2010","unstructured":"Saadoun D, Wechsler B, Terrada C, Hajage D, Le Thi HD, Resche-Rigon M, et al. Azathioprine in severe uveitis of Beh\u00e7et\u2019s disease. Arthritis Care Res. 2010;62:1733\u20138.","journal-title":"Arthritis Care Res"},{"key":"548_CR155","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1002\/art.21231","volume":"52","author":"I Tugal-Tutkun","year":"2005","unstructured":"Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Beh\u00e7et\u2019s disease: an open-label trial. Arthritis Rheum. 2005;52:2478\u201384.","journal-title":"Arthritis Rheum"},{"key":"548_CR156","volume-title":"Adamantiades-Beh\u00e7et\u2019s disease. Advances in experimental medicine and biology","author":"F Shahram","year":"2022","unstructured":"Shahram F, Davatchi F, Chams H, Nadji A, Jamshidi A, Akbarian M, et al. Azathioprine and low dose pulse cyclophosphamide in severe ocular lesions of Beh\u00e7et\u2019s disease. In: Zouboulis CC, editor., et al., Adamantiades-Beh\u00e7et\u2019s disease. Advances in experimental medicine and biology, vol. 528. Boston: Springer; 2022."},{"key":"548_CR157","first-page":"928","volume":"4","author":"V Hamuryudan","year":"2002","unstructured":"Hamuryudan V, Ozyazgan Y, Fresko Y, Mat C, Yurdakul S, Yazici H. Interferon alfa combined with azathioprine for the uveitis of Beh\u00e7et\u2019s disease: an open study. Isr Med Assoc J. 2002;4:928\u201330.","journal-title":"Isr Med Assoc J"},{"key":"548_CR158","first-page":"136","volume":"20","author":"D BenEzra","year":"1988","unstructured":"BenEzra D, Cohen E, Chajek T, Friedman G, Pizanti S, de Courten C, et al. Evaluation of conventional therapy versus cyclosporine A in Beh\u00e7et\u2019s syndrome. Transplant Proc. 1988;20:136\u201343.","journal-title":"Transplant Proc"},{"key":"548_CR159","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1136\/bjo.76.4.241","volume":"76","author":"Y Ozyazgan","year":"1992","unstructured":"Ozyazgan Y, Yurdakul S, Yazici H, T\u00fcz\u00fcn B, I\u015f\u00e7imen A, T\u00fcz\u00fcn Y, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Beh\u00e7et\u2019s syndrome: a single masked trial. Br J Ophthalmol. 1992;76:241\u20133.","journal-title":"Br J Ophthalmol"},{"key":"548_CR160","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.survophthal.2005.04.009","volume":"50","author":"C Evereklioglu","year":"2005","unstructured":"Evereklioglu C. Current concepts in the etiology and treatment of Beh\u00e7et disease. Surv Ophthalmol. 2005;50:297\u2013350.","journal-title":"Surv Ophthalmol"},{"key":"548_CR161","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.3390\/ijms21093072","volume":"21","author":"T van der Houwen","year":"2020","unstructured":"van der Houwen T, van Laar J. Beh\u04abet\u2019s disease, and the role of TNF-\u03b1 and TNF-\u03b1 blockers. Int J Mol Sci. 2020;21:3072.","journal-title":"Int J Mol Sci"},{"key":"548_CR162","doi-asserted-by":"publisher","first-page":"169","DOI":"10.4274\/tjo.galenos.2019.60308","volume":"50","author":"\u00d6P \u00c7akar","year":"2020","unstructured":"\u00c7akar \u00d6P. Beh\u00e7et\u2019s uveitis: current diagnostic and therapeutic approach. Turk J Ophthalmol. 2020;50:169\u201382.","journal-title":"Turk J Ophthalmol."},{"key":"548_CR163","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","volume":"121","author":"G Levy-Clarke","year":"2014","unstructured":"Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121:785-96.e3.","journal-title":"Ophthalmology"},{"key":"548_CR164","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0140-6736(01)05497-6","volume":"358","author":"PP Sfikakis","year":"2001","unstructured":"Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Beh\u00e7et\u2019s disease. Lancet. 2001;358:295\u20136.","journal-title":"Lancet"},{"key":"548_CR165","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1002\/art.41026","volume":"71","author":"B Atienza-Mateo","year":"2019","unstructured":"Atienza-Mateo B, Mart\u00edn-Varillas JL, Calvo-R\u00edo V, Demetrio-Pablo R, Beltr\u00e1n E, S\u00e1nchez-Burs\u00f3n J, et al. Comparative study of infliximab versus adalimumab in refractory uveitis due to Beh\u00e7et\u2019s disease: national multicenter study of 177 cases. Arthritis Rheumatol. 2019;71:2081\u20139.","journal-title":"Arthritis Rheumatol"},{"key":"548_CR166","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/rheumatology\/keq366","volume":"50","author":"N Markomichelakis","year":"2011","unstructured":"Markomichelakis N, Delicha E, Masselos S, Fragiadaki K, Kaklamanis P, Sfikakis PP. A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Beh\u00e7et\u2019s disease: a comparative 4-week study. Rheumatology. 2011;50:593\u20137.","journal-title":"Rheumatology"},{"key":"548_CR167","first-page":"1362","volume":"31","author":"S Ohno","year":"2004","unstructured":"Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Beh\u00e7et\u2019s disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362\u20138.","journal-title":"J Rheumatol"},{"key":"548_CR168","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1007\/s10384-010-0859-0","volume":"54","author":"T Ito","year":"2010","unstructured":"Ito T, Sonoda KH, Hijioka K, Fujimoto T, Ishibashi T. Acquired resistance to infliximab against uveitis due to Beh\u00e7et\u2019s disease after one year of administration. Jpn J Ophthalmol. 2010;54:502\u20134.","journal-title":"Jpn J Ophthalmol"},{"key":"548_CR169","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s10787-020-00697-4","volume":"28","author":"E Silvestri","year":"2020","unstructured":"Silvestri E, Bitossi A, Bettiol A, Emmi G, Urban ML, Mattioli I, et al. Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Beh\u00e7et\u2019s syndrome. Inflammopharmacology. 2020;28:711\u20138.","journal-title":"Inflammopharmacology"},{"key":"548_CR170","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s10067-016-3480-x","volume":"36","author":"C Fabiani","year":"2017","unstructured":"Fabiani C, Vitale A, Emmi G, Vannozzi L, Lopalco G, Guerriero S, et al. Efficacy and safety of adalimumab in Beh\u00e7et\u2019s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017;36:183\u20139.","journal-title":"Clin Rheumatol"},{"key":"548_CR171","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","volume":"62","author":"H Vallet","year":"2015","unstructured":"Vallet H, Riviere S, Sanna A, Deroux A, Moulis G, Addimanda O, et al. Efficacy of anti-TNF alpha in severe and\/or refractory Beh\u00e7et\u2019s disease: multicenter study of 124 patients. J Autoimmun. 2015;62:67\u201374.","journal-title":"J Autoimmun"},{"key":"548_CR172","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ajo.2022.02.002","volume":"238","author":"G Maalouf","year":"2022","unstructured":"Maalouf G, Andrillon A, Leclercq M, S\u00e8ve P, Bielefeld P, Gueudry J, et al. Lower relapses rate with infliximab versus adalimumab in sight-threatening uveitis: a multicenter study of 330 patients. Am J Ophthalmol. 2022;238:173\u201380.","journal-title":"Am J Ophthalmol"},{"key":"548_CR173","first-page":"S34","volume":"34","author":"M Santos-G\u00f3mez","year":"2016","unstructured":"Santos-G\u00f3mez M, Calvo-R\u00edo V, Blanco R, Beltr\u00e1n E, Mesquida M, Ad\u00e1n A, et al. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Beh\u00e7et\u2019s disease: results of a multicentre open-label study. Clin Exp Rheumatol. 2016;34:S34-40.","journal-title":"Clin Exp Rheumatol"},{"key":"548_CR174","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1080\/09273948.2017.1351573","volume":"27","author":"C Fabiani","year":"2019","unstructured":"Fabiani C, Sota J, Rigante D, Vitale A, Emmi G, Vannozzi L, et al. Rapid and sustained efficacy of golimumab in the treatment of multirefractory uveitis associated with Beh\u00e7et\u2019s disease. Ocul Immunol Inflamm. 2019;27:58\u201363.","journal-title":"Ocul Immunol Inflamm"},{"key":"548_CR175","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2147\/TCRM.S232660","volume":"16","author":"G Costagliola","year":"2020","unstructured":"Costagliola G, Cappelli S, Consolini R. Beh\u00e7et\u2019s disease in children: diagnostic and management challenges. Ther Clin Risk Manag. 2020;16:495\u2013507.","journal-title":"Ther Clin Risk Manag"},{"key":"548_CR176","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/1756-185X.12139","volume":"16","author":"F Davatchi","year":"2013","unstructured":"Davatchi F, Shams H, Shahram F, Nadji A, Chams-Davatchi C, Sadeghi Abdollahi B, et al. Methotrexate in ocular manifestations of Behcet\u2019s disease: a longitudinal study up to 15 years. Int J Rheum Dis. 2013;16:568\u201377.","journal-title":"Int J Rheum Dis"},{"key":"548_CR177","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/s10067-013-2443-8","volume":"34","author":"L Cantarini","year":"2015","unstructured":"Cantarini L, Vitale A, Scalini P, Dinarello CA, Rigante D, Franceschini R, et al. Anakinra treatment in drug-resistant Behcet\u2019s disease: a case series. Clin Rheumatol. 2015;34:1293\u2013301.","journal-title":"Clin Rheumatol"},{"key":"548_CR178","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s10067-016-3506-4","volume":"36","author":"C Fabiani","year":"2017","unstructured":"Fabiani C, Vitale A, Emmi G, Lopalco G, Vannozzi L, Guerriero S, et al. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Beh\u00e7et\u2019s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017;36:191\u20137.","journal-title":"Clin Rheumatol"},{"key":"548_CR179","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1136\/annrheumdis-2012-201383","volume":"71","author":"S Ugurlu","year":"2012","unstructured":"Ugurlu S, Ucar D, Seyahi E, Hatemi G, Yurdakul S. Canakinumab in a patient with juvenile Behcet\u2019s syndrome with refractory eye disease. Ann Rheum Dis. 2012;71:1589\u201391.","journal-title":"Ann Rheum Dis"},{"key":"548_CR180","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1080\/09273948.2018.1511810","volume":"28","author":"C Fabiani","year":"2020","unstructured":"Fabiani C, Vitale A, Rigante D, Emmi G, Lopalco G, Di Scala G, et al. The presence of uveitis Is associated with a sustained response to the interleukin (IL)-1 inhibitors anakinra and canakinumab in Beh\u00e7et\u2019s disease. Ocul Immunol Inflamm. 2020;28:298\u2013304.","journal-title":"Ocul Immunol Inflamm"},{"key":"548_CR181","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s10067-015-3004-0","volume":"35","author":"G Emmi","year":"2016","unstructured":"Emmi G, Talarico R, Lopalco G, Cimaz R, Cantini F, Viapiana O, et al. Efficacy and safety profile of anti-interleukin-1 treatment in Beh\u00e7et\u2019s disease: a multicenter retrospective study. Clin Rheumatol. 2016;35:1281\u20136.","journal-title":"Clin Rheumatol"},{"key":"548_CR182","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1136\/annrheumdis-2011-155143","volume":"71","author":"A G\u00fcl","year":"2012","unstructured":"G\u00fcl A, Tugal-Tutkun I, Dinarello CA, Reznikov L, Esen BA, Mirza A, et al. Interleukin-1\u03b2-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Beh\u00e7et\u2019s disease: an open-label pilot study. Ann Rheum Dis. 2012;71:563\u20136.","journal-title":"Ann Rheum Dis"},{"key":"548_CR183","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3109\/09273948.2015.1092558","volume":"25","author":"I Tugal-Tutkun","year":"2017","unstructured":"Tugal-Tutkun I, Kadayifcilar S, Khairallah M, Lee SC, Ozdal P, \u00d6zyazgan Y, et al. Safety and efficacy of gevokizumab in patients with Beh\u00e7et\u2019s disease uveitis: results of an exploratory phase 2 study. Ocul Immunol Inflamm. 2017;25:62\u201370.","journal-title":"Ocul Immunol Inflamm"},{"key":"548_CR184","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1080\/09273948.2017.1421233","volume":"26","author":"I Tugal-Tutkun","year":"2018","unstructured":"Tugal-Tutkun I, Pavesio C, De Cordoue A, Bernard-Poenaru O, G\u00fcl A. Use of gevokizumab in patients with Beh\u00e7et\u2019s disease uveitis: an international, randomized, double-masked, placebo-controlled study and open-label extension study. Ocul Immunol Inflamm. 2018;26:1023\u201333.","journal-title":"Ocul Immunol Inflamm"},{"issue":"4","key":"548_CR185","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1001\/archderm.138.4.467","volume":"138","author":"E Alpsoy","year":"2002","unstructured":"Alpsoy E, Durusoy C, Yilmaz E, Ozgurel Y, Ermis O, Yazar S, et al. Interferon alfa-2a in the treatment of Beh\u00e7et disease: a randomized placebo-controlled and double-blind study. Arch Dermatol. 2002;138(4):467\u201371.","journal-title":"Arch Dermatol"},{"key":"548_CR186","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/bjo.87.4.423","volume":"87","author":"I K\u00f6tter","year":"2003","unstructured":"K\u00f6tter I, Zierhut M, Eckstein AK, Vonthein R, Ness T, G\u00fcnaydin I, et al. Human recombinant interferon alfa-2a for the treatment of Beh\u00e7et\u2019s disease with sight threatening posterior or panuveitis. Br J Ophthalmol. 2003;87:423\u201331.","journal-title":"Br J Ophthalmol"},{"key":"548_CR187","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1007\/s10067-016-3318-6","volume":"35","author":"H Kavandi","year":"2016","unstructured":"Kavandi H, Khabbazi A, Kolahi S, Hajialilo M, Shayan FK, Oliaei M. Long-term efficacy and safety of interferon \u03b1-2a therapy in severe refractory ophthalmic Behcet\u2019s disease. Clin Rheumatol. 2016;35:2765\u20139.","journal-title":"Clin Rheumatol"},{"key":"548_CR188","first-page":"896","volume":"35","author":"L Krause","year":"2008","unstructured":"Krause L, Altenburg A, Pleyer U, K\u00f6hler AK, Zouboulis CC, Foerster MH. Longterm visual prognosis of patients with ocular Adamantiades-Beh\u00e7et\u2019s disease treated with interferon-alpha-2a. J Rheumatol. 2008;35:896\u2013903.","journal-title":"J Rheumatol"},{"key":"548_CR189","first-page":"129","volume":"101","author":"CME Deuter","year":"2004","unstructured":"Deuter CME, K\u00f6tter I, G\u00fcnaydin I, Zierhut M, St\u00fcbiger N. Ocular involvement in Beh\u00e7et\u2019s disease: first 5-year-results for visual development after treatment with interferon alfa-2a. Ophthalmol Z Dtsch Ophthalmol Ges. 2004;101:129\u201334.","journal-title":"Ophthalmol. Z Dtsch Ophthalmol Ges."},{"key":"548_CR190","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1002\/art.27581","volume":"62","author":"CME Deuter","year":"2010","unstructured":"Deuter CME, Zierhut M, M\u00f6hle A, Vonthein R, St\u00f6biger N, K\u00f6tter I. Long-term remission after cessation of interferon-\u03b1 treatment in patients with severe uveitis due to Beh\u00e7et\u2019s disease. Arthritis Rheum. 2010;62:2796\u2013805.","journal-title":"Arthritis Rheum"},{"key":"548_CR191","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.699903","volume":"12","author":"Y Qian","year":"2021","unstructured":"Qian Y, Qu Y, Gao F, Pei M, Liang A, Xiao J, et al. Comparison of the safety and efficacy of interferon alpha-2a and cyclosporine-A when combined with glucocorticoid in the treatment of refractory Beh\u00e7et\u2019s uveitis: a randomized controlled prospective study. Front Pharmacol. 2021;12: 699903.","journal-title":"Front Pharmacol"},{"key":"548_CR192","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1080\/09273948.2016.1206204","volume":"25","author":"E Diwo","year":"2017","unstructured":"Diwo E, Gueudry J, Saadoun D, Weschler B, LeHoang P, Bodaghi B. Long-term efficacy of interferon in severe uveitis associated with Beh\u00e7et disease. Ocul Immunol Inflamm. 2017;25:76\u201384.","journal-title":"Ocul Immunol Inflamm"},{"key":"548_CR193","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1080\/09273948.2020.1815797","volume":"30","author":"L De Simone","year":"2022","unstructured":"De Simone L, Invernizzi A, Aldigeri R, Mastrofilippo V, Marvisi C, Gozzi F, et al. Effectiveness of infliximab and interferon alpha-2a for the treatment of Beh\u00e7et\u2019s uveitis: customizing therapy according to the clinical features. Ocul Immunol Inflamm. 2022;30:506\u201314.","journal-title":"Ocul Immunol Inflamm"},{"key":"548_CR194","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.635663","volume":"12","author":"R Bursi","year":"2021","unstructured":"Bursi R, Cafaro G, Perricone C, Riccucci I, Calvacchi S, Gerli R, et al. Contribution of Janus-kinase\/signal transduction activator of transcription pathway in the pathogenesis of vasculitis: a possible treatment target in the upcoming future. Front Pharmacol. 2021;12: 635663.","journal-title":"Front Pharmacol"},{"key":"548_CR195","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032777","volume":"7","author":"C Liongue","year":"2012","unstructured":"Liongue C, O\u2019Sullivan LA, Trengove MC, Ward AC. Evolution of JAK-STAT pathway components: mechanisms and role in immune system development. PLoS ONE. 2012;7: e32777.","journal-title":"PLoS ONE"},{"key":"548_CR196","first-page":"641","volume":"26","author":"SJ Bing","year":"2020","unstructured":"Bing SJ, Lyu C, Xu B, Wandu WS, Hinshaw SJ, Furumoto Y, et al. Tofacitinib inhibits the development of experimental autoimmune uveitis and reduces the proportions of Th1 but not of Th17 cells. Mol Vis. 2020;26:641\u201351.","journal-title":"Mol Vis"},{"key":"548_CR197","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s10067-019-04875-w","volume":"39","author":"E Miserocchi","year":"2020","unstructured":"Miserocchi E, Giuffr\u00e8 C, Cornalba M, Pontikaki I, Cimaz R. JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis. Clin Rheumatol. 2020;39:847\u201351.","journal-title":"Clin Rheumatol"},{"key":"548_CR198","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1080\/09273948.2019.1605453","volume":"27","author":"P Bauermann","year":"2019","unstructured":"Bauermann P, Heiligenhaus A, Heinz C. Effect of Janus kinase inhibitor treatment on anterior uveitis and associated macular edema in an adult patient with juvenile idiopathic arthritis. Ocul Immunol Inflamm. 2019;27:1232\u20134.","journal-title":"Ocul Immunol Inflamm"},{"key":"548_CR199","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ajoc.2018.12.001","volume":"13","author":"MA Paley","year":"2019","unstructured":"Paley MA, Karacal H, Rao PK, Margolis TP, Miner JJ. Tofacitinib for refractory uveitis and scleritis. Am J Ophthalmol Case Rep. 2019;13:53\u20135.","journal-title":"Am J Ophthalmol Case Rep."},{"key":"548_CR200","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.784860","volume":"12","author":"XB Liu","year":"2021","unstructured":"Liu XB, Tang LS, Chen JW, Lin CS, Liu QH, Xu Q. Case report: a promising treatment strategy for noninfectious uveitis. Front Pharmacol. 2021;12: 784860.","journal-title":"Front Pharmacol"},{"key":"548_CR201","doi-asserted-by":"publisher","first-page":"7140","DOI":"10.1038\/s41598-022-10777-w","volume":"12","author":"L Hoisnard","year":"2022","unstructured":"Hoisnard L, Lebrun-Vignes B, Maury S, Mahevas M, El Karoui K, Roy L, et al. Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database. Sci Rep. 2022;12:7140.","journal-title":"Sci Rep"},{"key":"548_CR202","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1080\/14728214.2020.1847271","volume":"25","author":"I Tugal-Tutkun","year":"2020","unstructured":"Tugal-Tutkun I, \u00c7akar \u00d6P. Beh\u00e7et\u2019s disease uveitis: is there a need for new emerging drugs? Expert Opin Emerg Drugs. 2020;25:531\u201347.","journal-title":"Expert Opin Emerg Drugs"},{"issue":"2","key":"548_CR203","first-page":"1084","volume":"1998","author":"A Saenz","year":"2000","unstructured":"Saenz A, Ausejo M, Shea B, Wells G, Welch V, Tugwell P. Pharmacotherapy for Behcet\u2019s syndrome. Cochrane Database Syst Rev. 2000;1998(2):1084.","journal-title":"Cochrane Database Syst Rev"},{"key":"548_CR204","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","volume":"120","author":"AD Dick","year":"2013","unstructured":"Dick AD, Tugal-Tutkun I, Foster S, Zierhut M, Melissa Liew SH, Bezlyak V, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013;120:777\u201387.","journal-title":"Ophthalmology"},{"key":"548_CR205","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s00384-016-2728-x","volume":"32","author":"J Park","year":"2017","unstructured":"Park J, Cheon JH, Park YE, Lee YJ, Lee HJ, Park SJ, et al. Risk factors and outcomes of acute lower gastrointestinal bleeding in intestinal Beh\u00e7et\u2019s disease. Int J Colorectal Dis. 2017;32:745\u201351.","journal-title":"Int J Colorectal Dis"},{"key":"548_CR206","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003348","volume":"95","author":"I Hatemi","year":"2016","unstructured":"Hatemi I, Esatoglu SN, Hatemi G, Erzin Y, Yazici H, Celik AF. Characteristics, treatment, and long-term outcome of gastrointestinal involvement in Behcet\u2019s syndrome: a strobe-compliant observational study from a dedicated multidisciplinary center. Medicine (Baltimore). 2016;95: e3348.","journal-title":"Medicine (Baltimore)"},{"key":"548_CR207","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00535-007-2090-4","volume":"42","author":"K Kobayashi","year":"2007","unstructured":"Kobayashi K, Ueno F, Bito S, Iwao Y, Fukushima T, Hiwatashi N, et al. Development of consensus statements for the diagnosis and management of intestinal Beh\u00e7et\u2019s disease using a modified Delphi approach. J Gastroenterol. 2007;42:737\u201345.","journal-title":"J Gastroenterol"},{"key":"548_CR208","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1111\/jgh.14690","volume":"34","author":"H Kinoshita","year":"2019","unstructured":"Kinoshita H, Nishioka H, Ikeda A, Ikoma K, Sameshima Y, Ohi H, et al. Remission induction, maintenance, and endoscopic outcome with oral 5-aminosalicylic acid in intestinal Beh\u00e7et\u2019s disease. J Gastroenterol Hepatol. 2019;34:1929\u201339.","journal-title":"J Gastroenterol Hepatol"},{"key":"548_CR209","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1053\/gast.2001.22556","volume":"120","author":"PV Hassard","year":"2001","unstructured":"Hassard PV, Binder SW, Nelson V, Vasiliauskas EA. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Beh\u00e7et\u2019s disease: a case report. Gastroenterology. 2001;120:995\u20139.","journal-title":"Gastroenterology"},{"key":"548_CR210","first-page":"1833","volume":"19","author":"JH Lee","year":"2013","unstructured":"Lee JH, Cheon JH, Jeon SW, Ye BD, Yang SK, Kim YH, et al. Efficacy of infliximab in intestinal Beh\u00e7et\u2019s disease: a Korean multicenter retrospective study. Inflamm Bowel Dis. 2013;19:1833\u20138.","journal-title":"Inflamm Bowel Dis"},{"key":"548_CR211","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003863","volume":"95","author":"T Hibi","year":"2016","unstructured":"Hibi T, Hirohata S, Kikuchi H, Tateishi U, Sato N, Ozaki K, et al. Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore). 2016;95: e3863.","journal-title":"Medicine (Baltimore)"},{"key":"548_CR212","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3109\/s10165-010-0370-y","volume":"21","author":"S Iwata","year":"2011","unstructured":"Iwata S, Saito K, Yamaoka K, Tsujimura S, Nawata M, Hanami K, et al. Efficacy of combination therapy of anti-TNF-\u03b1 antibody infliximab and methotrexate in refractory entero-Beh\u00e7et\u2019s disease. Mod Rheumatol. 2011;21:184\u201391.","journal-title":"Mod Rheumatol"},{"key":"548_CR213","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.cgh.2014.08.042","volume":"13","author":"S Tanida","year":"2015","unstructured":"Tanida S, Inoue N, Kobayashi K, Naganuma M, Hirai F, Iizuka B, et al. Adalimumab for the treatment of Japanese patients with intestinal Beh\u00e7et\u2019s disease. Clin Gastroenterol Hepatol. 2015;13:940-8.e3.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"548_CR214","doi-asserted-by":"publisher","first-page":"395","DOI":"10.5217\/ir.2017.15.3.395","volume":"15","author":"N Inoue","year":"2017","unstructured":"Inoue N, Kobayashi K, Naganuma M, Hirai F, Ozawa M, Arikan D, et al. Long-term safety and efficacy of adalimumab for intestinal Beh\u00e7et\u2019s disease in the open label study following a phase 3 clinical trial. Intest Res. 2017;15:395\u2013401.","journal-title":"Intest Res"},{"key":"548_CR215","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.dld.2018.10.024","volume":"51","author":"N Sugimura","year":"2019","unstructured":"Sugimura N, Mizoshita T, Sugiyama T, Togawa S, Miyaki T, Suzuki T, et al. Real-world efficacy of adalimumab and infliximab for refractory intestinal Beh\u00e7et\u2019s disease. Dig Liver Dis. 2019;51:967\u201371.","journal-title":"Dig Liver Dis"},{"key":"548_CR216","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.1111\/j.1572-0241.1999.01532.x","volume":"94","author":"PS Kim","year":"1999","unstructured":"Kim PS, Zlatanic J, Korelitz BI, Gleim GW. Optimum duration of treatment with 6-mercaptopurine for Crohn\u2019s disease. Am J Gastroenterol. 1999;94:3254\u20137.","journal-title":"Am J Gastroenterol"},{"key":"548_CR217","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/ibd.21757","volume":"18","author":"YS Jung","year":"2012","unstructured":"Jung YS, Cheon JH, Hong SP, Kim TI, Kim WH. Clinical outcomes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behcet\u2019s disease. Inflamm Bowel Dis. 2012;18:750\u20137.","journal-title":"Inflamm Bowel Dis"},{"key":"548_CR218","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1053\/j.gastro.2013.11.024","volume":"146","author":"BG Feagan","year":"2014","unstructured":"Feagan BG, McDonald JWD, Panaccione R, Enns RA, Bernstein CN, Ponich TP, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn\u2019s disease. Gastroenterology. 2014;146:681-8.e1.","journal-title":"Gastroenterology"},{"key":"548_CR219","doi-asserted-by":"publisher","first-page":"315","DOI":"10.5217\/ir.2018.16.2.315","volume":"16","author":"J Park","year":"2018","unstructured":"Park J, Cheon JH, Park Y, Park SJ, Kim TI, Kim WH. Efficacy and tolerability of methotrexate therapy for refractory intestinal Beh\u00e7et\u2019s disease: a single center experience. Intest Res. 2018;16:315\u20138.","journal-title":"Intest Res"},{"key":"548_CR220","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1046\/j.1365-2796.1998.00159.x","volume":"243","author":"S Georgiou","year":"1998","unstructured":"Georgiou S, Monastirli A, Pasmatzi E, Gartaganis S, Goerz G, Tsambaos D. Efficacy and safety of systemic recombinant interferon-alpha in Beh\u00e7et\u2019s disease. J Intern Med. 1998;243:367\u201372.","journal-title":"J Intern Med"},{"key":"548_CR221","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1345\/aph.1D524","volume":"38","author":"M Sayarlioglu","year":"2004","unstructured":"Sayarlioglu M, Kotan MC, Topcu N, Bayram I, Arslanturk H, Gul A. Treatment of recurrent perforating intestinal ulcers with thalidomide in Beh\u00e7et\u2019s disease. Ann Pharmacother. 2004;38:808\u201311.","journal-title":"Ann Pharmacother"},{"key":"548_CR222","first-page":"S129","volume":"33","author":"I Hatemi","year":"2015","unstructured":"Hatemi I, Hatemi G, Pamuk ON, Erzin Y, Celik AF. TNF-alpha antagonists and thalidomide for the management of gastrointestinal Beh\u00e7et\u2019s syndrome refractory to the conventional treatment modalities: a case series and review of the literature. Clin Exp Rheumatol. 2015;33:S129\u201337.","journal-title":"Clin Exp Rheumatol"},{"key":"548_CR223","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1136\/annrheumdis-2020-217307","volume":"79","author":"J Liu","year":"2020","unstructured":"Liu J, Hou Y, Sun L, Li C, Li L, Zhao Y, et al. A pilot study of tofacitinib for refractory Beh\u00e7et\u2019s syndrome. Ann Rheum Dis. 2020;79:1517\u201320.","journal-title":"Ann Rheum Dis"},{"key":"548_CR224","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.2169\/internalmedicine.4705-20","volume":"59","author":"S Hirohata","year":"2020","unstructured":"Hirohata S, Kikuchi H, Sawada T, Okada M, Takeno M, Kuwana M, et al. Recommendations for the management of neuro-Beh\u00e7et\u2019s disease by the Japanese National Research Committee for Beh\u00e7et\u2019s disease. Intern Med. 2020;59:2359\u201367.","journal-title":"Intern Med"},{"key":"548_CR225","doi-asserted-by":"publisher","first-page":"961","DOI":"10.3109\/14397595.2014.891496","volume":"24","author":"S Hirohata","year":"2014","unstructured":"Hirohata S, Kikuchi H, Sawada T, Nagafuchi H, Kuwana M, Takeno M, et al. Analysis of various factors on the relapse of acute neurological attacks in Beh\u00e7et\u2019s disease. Mod Rheumatol. 2014;24:961\u20135.","journal-title":"Mod Rheumatol"},{"key":"548_CR226","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.624795","volume":"8","author":"E Alpsoy","year":"2021","unstructured":"Alpsoy E, Leccese P, Emmi G, Ohno S. Treatment of Beh\u00e7et\u2019s disease: an algorithmic multidisciplinary approach. Front Med. 2021;8: 624795.","journal-title":"Front Med"},{"key":"548_CR227","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0022-510X(98)00165-8","volume":"159","author":"S Hirohata","year":"1998","unstructured":"Hirohata S, Suda H, Hashimoto T. Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behcet\u2019s disease. J Neurol Sci. 1998;159:181\u20135.","journal-title":"J Neurol Sci"},{"key":"548_CR228","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/0-306-48382-3_117","volume":"528","author":"H Kikuchi","year":"2003","unstructured":"Kikuchi H, Aramaki K, Hirohata S. Low dose MTX for progressive neuro-Beh\u00e7et\u2019s disease: a follow-up study for 4 years. Adv Exp Med Biol. 2003;528:575\u20138.","journal-title":"Adv Exp Med Biol"},{"key":"548_CR229","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jns.2015.01.005","volume":"349","author":"S Hirohata","year":"2015","unstructured":"Hirohata S, Kikuchi H, Sawada T, Nagafuchi H, Kuwana M, Takeno M, et al. Retrospective analysis of long-term outcome of chronic progressive neurological manifestations in Behcet\u2019s disease. J Neurol Sci. 2015;349:143\u20138.","journal-title":"J Neurol Sci"},{"key":"548_CR230","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1007\/s00415-013-7209-3","volume":"261","author":"S Kalra","year":"2014","unstructured":"Kalra S, Silman A, Akman-Demir G, Bohlega S, Borhani-Haghighi A, Constantinescu CS, et al. Diagnosis and management of neuro-Beh\u00e7et\u2019s disease: international consensus recommendations. J Neurol. 2014;261:1662\u201376.","journal-title":"J Neurol"},{"key":"548_CR231","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/art.23345","volume":"59","author":"N Pipitone","year":"2008","unstructured":"Pipitone N, Olivieri I, Padula A, D\u2019angelo S, Nigro A, Zuccoli G, et al. Infliximab for the treatment of neuro-Beh\u00e7et\u2019s disease: a case series and review of the literature. Arthritis Rheum. 2008;59:285\u201390.","journal-title":"Arthritis Rheum"},{"key":"548_CR232","first-page":"S133","volume":"26","author":"J Belzunegui","year":"2008","unstructured":"Belzunegui J, L\u00f3pez L, Paniagua I, Intxausti JJ, Ma\u00edz O. Efficacy of infliximab and adalimumab in the treatment of a patient with severe neuro-Beh\u00e7et\u2019s disease. Clin Exp Rheumatol. 2008;26:S133\u20134.","journal-title":"Clin Exp Rheumatol"},{"key":"548_CR233","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000258","volume":"3","author":"B Zeydan","year":"2016","unstructured":"Zeydan B, Uygunoglu U, Saip S, Demirci ON, Seyahi E, Ugurlu S, et al. Infliximab is a plausible alternative for neurologic complications of Beh\u00e7et disease. Neurol Neuroimmunol Neuroinflam. 2016;3: e258.","journal-title":"Neurol Neuroimmunol Neuroinflam."},{"key":"548_CR234","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003550","volume":"95","author":"AC Desbois","year":"2016","unstructured":"Desbois AC, Addimanda O, Bertrand A, Deroux A, P\u00e9rard L, Depaz R, et al. Efficacy of anti-TNF\u03b1 in severe and refractory neuro-Behcet disease: an observational study. Medicine (Baltimore). 2016;95: e3550.","journal-title":"Medicine (Baltimore)"},{"key":"548_CR235","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11910-017-0742-1","volume":"17","author":"E Kemanetzoglou","year":"2017","unstructured":"Kemanetzoglou E, Andreadou E. CNS demyelination with TNF-\u03b1 blockers. Curr Neurol Neurosci Rep. 2017;17:36.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"548_CR236","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/0049-0172(86)90020-X","volume":"15","author":"PJ Clements","year":"1986","unstructured":"Clements PJ, Davis J. Cytotoxic drugs: their clinical application to the rheumatic diseases. Semin Arthritis Rheum. 1986;15:231\u201354.","journal-title":"Semin Arthritis Rheum"},{"key":"548_CR237","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102898","volume":"20","author":"G Ruiz-Irastorza","year":"2021","unstructured":"Ruiz-Irastorza G, Due\u00f1a-Bartolome L, Dunder S, Varona J, Gomez-Carballo C, Dominguez-Cainzos J, et al. Eurolupus cyclophosphamide plus repeated pulses of methyl-prednisolone for the induction therapy of class III, IV and V lupus nephritis. Autoimmun Rev. 2021;20: 102898.","journal-title":"Autoimmun Rev"},{"key":"548_CR238","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000026733","volume":"100","author":"C Speer","year":"2021","unstructured":"Speer C, Altenm\u00fcller-Walther C, Splitthoff J, Nusshag C, K\u00e4lble F, Reichel P, et al. Cyclophosphamide induction dose and outcomes in ANCA-associated vasculitis with renal involvement: a comparative cohort study. Medicine (Baltimore). 2021;100: e26733.","journal-title":"Medicine (Baltimore)"},{"key":"548_CR239","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3164\/jcbn.20-197","volume":"69","author":"H Kurokawa","year":"2021","unstructured":"Kurokawa H, Taninaka A, Shigekawa H, Matsui H. The cytotoxicity of cyclophosphamide is enhanced in combination with monascus pigment. J Clin Biochem Nutr. 2021;69:131\u20136.","journal-title":"J Clin Biochem Nutr."},{"key":"548_CR240","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.neurol.2011.09.006","volume":"168","author":"EH Ait Ben Haddou","year":"2012","unstructured":"Ait Ben Haddou EH, Imounan F, Regragui W, Mouti O, Benchakroune N, Abouqal R, et al. Neurological manifestations of Beh\u00e7et\u2019s disease: evaluation of 40 patients treated by cyclophosphamide. Rev Neurol. 2012;168:344\u20139.","journal-title":"Rev Neurol"},{"key":"548_CR241","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1093\/rheumatology\/kez598","volume":"59","author":"M Gurcan","year":"2020","unstructured":"Gurcan M, Esatoglu SN, Hamuryudan V, Saygin D, Ugurlu S, Seyahi E, et al. Long term follow-up of Beh\u00e7et\u2019s syndrome patients treated with cyclophosphamide. Rheumatology. 2020;59:2264\u201371.","journal-title":"Rheumatology"},{"key":"548_CR242","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1093\/rheumatology\/ken172","volume":"47","author":"JB Kuemmerle-Deschner","year":"2008","unstructured":"Kuemmerle-Deschner JB, Tzaribachev N, Deuter C, Zierhut M, Batra M, Koetter I. Interferon-alpha: a new therapeutic option in refractory juvenile Beh\u00e7et\u2019s disease with CNS involvement. Rheumatology. 2008;47:1051\u20133.","journal-title":"Rheumatology"},{"key":"548_CR243","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/00041327-200106000-00011","volume":"21","author":"JC Nichols","year":"2001","unstructured":"Nichols JC, Ince A, Akduman L, Mann ES. Interferon-alpha 2a treatment of neuro-Behcet disease. J Neuro-Ophthalmol. 2001;21:109\u201311.","journal-title":"J Neuro-Ophthalmol."},{"key":"548_CR244","first-page":"S64","volume":"29","author":"E Shugaiv","year":"2011","unstructured":"Shugaiv E, T\u00fcz\u00fcn E, Mutlu M, Kiyat-Atamer A, Kurtuncu M, Akman-Demir G. Mycophenolate mofetil as a novel immunosuppressant in the treatment of neuro-Beh\u00e7et\u2019s disease with parenchymal involvement: presentation of four cases. Clin Exp Rheumatol. 2011;29:S64-67.","journal-title":"Clin Exp Rheumatol"},{"key":"548_CR245","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.595984","volume":"12","author":"C Zhao","year":"2021","unstructured":"Zhao C, Li C, Duan FJ, Yan Q, Zhang Z, Du Y, et al. Case report: repeated low-dose rituximab treatment is effective in relapsing neuro Beh\u00e7et\u2019s disease. Front Neurol. 2021;12: 595984.","journal-title":"Front Neurol"},{"key":"548_CR246","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1007\/s00415-015-7897-y","volume":"262","author":"DP Kidd","year":"2015","unstructured":"Kidd DP. Rituximab is effective in severe treatment-resistant neurological Beh\u00e7et\u2019s syndrome. J Neurol. 2015;262:2676\u20137.","journal-title":"J Neurol"},{"key":"548_CR247","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1177\/1759720X20971908","volume":"12","author":"J Liu","year":"2020","unstructured":"Liu J, Yan D, Wang Z, Yang Y, Zhang S, Wu D, et al. Tocilizumab in the treatment of severe and refractory parenchymal neuro-Beh\u00e7et\u2019s syndrome: case series and literature review. Ther Adv Musculoskelet Dis. 2020;12:1759.","journal-title":"Ther Adv Musculoskelet Dis."},{"key":"548_CR248","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.neurol.2017.02.006","volume":"173","author":"L Essaadouni","year":"2017","unstructured":"Essaadouni L, Ha-Ou-Nou FZ. Efficacy and safety of tocilizumab in neuro-Beh\u00e7et\u2019s disease: a case report. Rev Neurol. 2017;173:171\u20132.","journal-title":"Rev Neurol"},{"key":"548_CR249","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101906","volume":"39","author":"A Borhani-Haghighi","year":"2019","unstructured":"Borhani-Haghighi A, Kardeh B, Banerjee S, Yadollahikhales G, Safari A, Sahraian MA, et al. Neuro-Behcet\u2019s disease: an update on diagnosis, differential diagnoses, and treatment. Mult Scler Relat Disord. 2019;39: 101906.","journal-title":"Mult Scler Relat Disord."},{"key":"548_CR250","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1046\/j.1442-9071.2001.00445.x","volume":"29","author":"Y Kato","year":"2001","unstructured":"Kato Y, Numaga J, Kato S, Kaburaki T, Kawashima H, Fujino Y. Central nervous system symptoms in a population of Beh\u00e7et\u2019s disease patients with refractory uveitis treated with cyclosporine A. Clin Exp Ophthalmol. 2001;29:335\u20136.","journal-title":"Clin Exp Ophthalmol"},{"key":"548_CR251","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1007\/s10067-005-0070-8","volume":"25","author":"I K\u00f6tter","year":"2006","unstructured":"K\u00f6tter I, G\u00fcnaydin I, Batra M, Vonthein R, St\u00fcbiger N, Fierlbeck G, et al. CNS involvement occurs more frequently in patients with Beh\u00e7et\u2019s disease under cyclosporin A (CSA) than under other medications: results of a retrospective analysis of 117 cases. Clin Rheumatol. 2006;25:482\u20136.","journal-title":"Clin Rheumatol"},{"key":"548_CR252","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/1756-185X.13778","volume":"23","author":"A Aksoy","year":"2020","unstructured":"Aksoy A, Yazici A, Omma A, Cefle A, Onen F, Tasdemir U, et al. Efficacy of TNF\u03b1 inhibitors for refractory vascular Beh\u00e7et\u2019s disease: a multicenter observational study of 27 patients and a review of the literature. Int J Rheum Dis. 2020;23:256\u201361.","journal-title":"Int J Rheum Dis"},{"key":"548_CR253","first-page":"2057","volume":"57","author":"Y Ding","year":"2018","unstructured":"Ding Y, Li C, Liu J, Yu X, Wang Y, Shi J, et al. Tocilizumab in the treatment of severe and\/or refractory vasculo-Beh\u00e7et\u2019s disease: a single-centre experience in China. Rheumatology. 2018;57:2057\u20139.","journal-title":"Rheumatology"},{"key":"548_CR254","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000494","volume":"94","author":"F Alibaz-Oner","year":"2015","unstructured":"Alibaz-Oner F, Karadeniz A, Ylmaz S, Balkarl A, Kimyon G, Yazc A, et al. Beh\u00e7et disease with vascular involvement: effects of different therapeutic regimens on the incidence of new relapses. Medicine (Baltimore). 2015;94: e494.","journal-title":"Medicine (Baltimore)"},{"key":"548_CR255","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1002\/art.34450","volume":"64","author":"AC Desbois","year":"2012","unstructured":"Desbois AC, Wechsler B, Resche-Rigon M, Piette JC, Huong DLT, Amoura Z, et al. Immunosuppressants reduce venous thrombosis relapse in Beh\u00e7et\u2019s disease. Arthritis Rheum. 2012;64:2753\u201360.","journal-title":"Arthritis Rheum"},{"key":"548_CR256","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s10067-007-0685-z","volume":"27","author":"JK Ahn","year":"2008","unstructured":"Ahn JK, Lee YS, Jeon CH, Koh EM, Cha HS. Treatment of venous thrombosis associated with Behcet\u2019s disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. Clin Rheumatol. 2008;27:201\u20135.","journal-title":"Clin Rheumatol"},{"key":"548_CR257","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1378\/chest.127.6.2243","volume":"127","author":"O Uzun","year":"2005","unstructured":"Uzun O, Akpolat T, Erkan L. Pulmonary vasculitis in Behcet disease: a cumulative analysis. Chest. 2005;127:2243\u201353.","journal-title":"Chest"},{"key":"548_CR258","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s11239-022-02637-1","volume":"54","author":"N Toledo-Samaniego","year":"2022","unstructured":"Toledo-Samaniego N, Oblitas CM, Pe\u00f1aloza-Mart\u00ednez E, del Toro-Cervera J, Alvarez-Sala-Walther LA, Demelo-Rodr\u00edguez P, et al. Arterial and venous involvement in Beh\u00e7et\u2019s syndrome: a narrative review. J Thromb Thrombolysis. 2022;54:162\u201371.","journal-title":"J Thromb Thrombolysis"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-022-00548-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-022-00548-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-022-00548-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:13:19Z","timestamp":1744715599000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-022-00548-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,10]]},"references-count":258,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["548"],"URL":"https:\/\/doi.org\/10.1007\/s40272-022-00548-5","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,10]]},"assertion":[{"value":"20 November 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No sources of funding were received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Teresa Giani, Angela Flavia Luppino, and Giovanna Ferrara have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data discussed in this article were a re-analysis of existing data, which are openly available at locations cited in the References section.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"TG wrote and edited the manuscript and GF and FL contributed to the data collection and wrote the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}